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Abstract 
Chemical proteomics has acquired a pivotal role in chemical biology because 
of its peculiar capability to deeply analyze the proteome from many points of 
view. Proteins identification, characterization and quantification provide a 
detailed portrait of a biological system. In particular, pharmaceutical research 
is looking with interest at chemical proteomics because the mechanism of 
action of bioactive molecules remains one of the main challenge[1]. 
Particularly, the identification of target proteins and investigation of ligand-
receptor interactions are today considered essential steps in the drug discovery 
and development process. Affinity purification-based mass spectrometry 
approaches (AP-MS) have emerged as a valuable mean to link bioactive 
compounds to their cellular targets[2]. In recent years, the application of such 
techniques led to successful results in determining the macromolecular 
partners of many interesting bioactive molecules[3,4]. These techniques require 
the chemical modifications of the molecule of interest onto a solid matrix, in 
order to allow the bioactive compound to “fish out” its specific interactors 
from a cell lysate or a tissue extract. Once eluted, these cellular targets are 
identified by MS and bioinformatics analysis[5,6]. Later on, the biological 
profile of the selected compound toward its cellular interactors is investigated 
by in vitro and/or in vivo assays.  
The application of this strategy to the cases of suvanine (SUV)[7], heteronemin 
(HET)[8,9] and scalaradial (SLD)[10,11] led to the identification of their main 
cellular targets. The identified interactions were then validated by means of 
surface plasmon resonance, whereas their biological relevance was established 
through in vitro and in vivo assays. 
An in cell fishing for partners procedure was also developed and applied to the 
case of SLD and Oleochantal (OLC)[12]. 
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Eventually,  a competition variant of the standard AP-MS approach was also 
performed to analyze the interactome of the endogenous metabolite, 3’-5’-
cyclic cytidine monophosphate (cCMP). 
HSP60 has been identified as the main biological target of SUV in HeLa cells, 
and its ability in inhibiting the HSP60 activity was demonstrated in vitro, 
evaluating the reduction of HSP60 mediated refolding of citrate synthase. 
HET was found to bind TDP43, a nucleic acid-binding protein involved in 
some neurodegenerative diseases. A marked effect of HET in lowering the 
binding affinity between TDP43 and the TAR32 oligonucleotide has been 
established by alpha screen technology. Moreover, a high tendency of TDP43 
to aggregate upon HET treatment was demonstrated in vitro, by using 
recombinant TDP43, and in cell, trough western blot and immunofluorescence 
analyses.  
Peroxiredoxin 1 and 14-3-3 ε were recognized as main cellular partners of 
SLD, by applying the described AP-MS approach.  
Later on, SLD was chosen as a probe for the development of an in cell fishing 
for partners experiment based on bio-orthogonal chemistry[13,14]. SLD was 
first decorated with an azide-containing linker and then a living cell sample 
was treated with the tagged molecule. The SLD interactors, selected in the 
cellular environment, were then fished out by promoting an azide-alkyne 
cycloaddition between the tagged SLD and an acetylenic functionalized 
matrix. Peroxiredoxin 1 and 14-3-3 ε, along with proteasome, were recovered 
as specific and main SLD partners. The effectiveness of bio-orthogonal 
chemistry in affinity-based target discovery experiments was further 
confirmed assessing the ability of Oleocanthal to select HSP90, its already 
known target[15].  
The cCMP interactome was deeply analyzed by means of AP-MS and 
competition experiments showing, along with the known partners PKA and 
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PKG[16], the heterogeneous nuclear ribonucleoproteins as a new class of 
potential cCMP effectors. 
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1.  Introduction 
 
In the post-genomic era, several “omics” sciences have been developed, 
aiming to depict the bio-functional effectors of genomic-encoded instructions. 
Particularly, proteomics is emerged as key technique because of its 
effectiveness in identification, characterization and quantification of 
proteins[1,2].  
The proteome is characterized by a high complexity because, in addition to the 
high amount of proteins expressed, is dynamically modulated during the time 
and by xenobiotics[3]. Thus, mass-spectrometric based approaches have 
acquired a pivotal role in the proteomic field because of their peculiar 
capability to analyse thousands of proteins in a single-large-scale experiment, 
providing detailed portraits of biological systems[4].  
The growing impact of mass spectrometry in proteomics has driven a very 
rapid progress in terms of sensitivity, resolution, mass accuracy, and mass 
spectrometers scan rate[5,6]. At the same time, new strategies for 
proteins/peptides separation have been developed to maximize mass 
spectrometers performance, whereas bio-informatics advances have made the 
data analysis process simpler and more exhaustive[7]. Indeed, due to its 
comprehensiveness and versatility, mass spectrometry-based chemical 
proteomics is now considered one of the key techniques in many fields of 
chemical biology[8]. In particular, pharmaceutical research is looking with 
interest at chemical proteomics because, even if the knowledge of the 
molecular mechanism of action is not essential for the discovery of new 
potential therapeutic agents, the identification of their cellular targets may 
facilitate the drug development. Moreover, these data are also useful to clarify 
the pharmacological and toxicological profile of a lead compound in a very 
early stage of D&D process.  
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Definitely, the simplified concept of one drug-one target is currently losing credit, 
whereas the idea that drugs may simultaneously target several proteins is spreading 
around, opening the way to new approaches of investigation[9].  
Chemical proteomics is a multi-faced technique that encloses different disciplines 
such as chemical biology, organic chemistry and biochemistry, useful for the analysis 
of different aspects of proteins, such as their function, structures, interactions, 
expression alteration etc. Several chemical proteomic methodologies have been 
recently developed and, among them, three are considered particularly powerful, 
mainly in the field of pharmaceutical research: (a) global proteomics is useful to  
weigh the alterations in the proteins expression upon drug treatment, while (b) 
compound centric chemical proteomics (CCCP) matches bioactive compounds with 
their macromolecular targets, and (c) activity based protein profiling (ABPP) is 
applied to visualize the alteration of enzyme activities after external stimuli. The 
following chapters will focus on the main experimental aspects and recent 
developments of the above-mentioned approaches. 
 
 
1.1 Mass spectrometry in proteomics: outlines 
 
The informations about a protein identity can be retrieved by analysis of the 
intact macromolecule or its proteolytic peptides (Figure 1). The so called 
“top-down” approach is based on the LC-MSMS analysis of intact 
proteins[10,11]. The handling of intact proteins is a crucial point in a MS 
experiment, first of all because of the solubility in MS friendly (detergent-free) 
buffers. Besides, the fractionation, ionization and fragmentation efficiency are 
more complicated in respect to peptides, and for these reasons top down 
approaches are not yet largely employed.  
Peptide analysis, in the “bottom up” approach,  is actually more feasible and, 
therefore, a huge number of experimental workflows have been introduced to 
maximize the information accessible from a single large-scale experiment[12]. 
   Introduction 
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Figure 1. Representation of “top down”, “bottom up” and shotgun approaches 
 
The analysis of a complex peptide sample is based on the selection of 
appropriate fractionation methods, required both at protein and peptide levels. 
One of the first strategies (still very popular) relies on the separation of protein 
sample by means of 2D or 1D gel electrophoresis[13,14]. In a two-dimensional 
poly-acrylamide gel electrophoresis experiment (2D-PAGE), proteins are first 
separated on the basis of their isoelectric point (pI). During this step, named 
isoelectric focusing (IEF), proteins are loaded onto polyacrylamide gels (IEF 
gels) or immobilized pH gradient strips (IPG) and an electrical field is applied, 
allowing proteins to migrate through the pH gradient until they reach their pI. 
Later on, proteins are treated with sodium dodecyl sulphate (SDS), that 
confers them a charge roughly proportional to their molecular weight, and 
separated by application of an electric potential. Protein spots are detected by 
means of visible, such as silver and Coomassie, or fluorescent stains, such as 
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Sypro Ruby and Deep Purple. Then, after excision from the gel, proteins are 
digested in situ with a proteolytic enzyme (mostly trypsin) to give the final 
peptides mixture. 2D-PAGE has an excellent resolving power and up to 10000 
spots may be visualized on a large scale run[15]. However, the procedure is 
time consuming and requires large sample amounts[16]. For these reasons, 1D 
gel electrophoresis coupled to a liquid chromatography separation (Gel-LC-
MS) step is largely preferred. In a 1D-PAGE, proteins are separated only 
according to their molecular weight[17]. The entire gel lanes are then cut in 
small pieces and subjected to in-gel proteolysis[18]. The peptide mixtures are 
finally separated and analysed trough liquid chromatography coupled to mass-
spectrometry. In order to improve sensitivity, the separation phase is usually 
performed in the nanoflow scale. Columns with a particle size in the order of 1 
µm are directly interfaced with nano-electrospray sources, improving both 
peptide separation and sensitivity[19]. 
Gel-based methods still suffer of some drawbacks, mainly the loss of sample 
due to an incomplete extraction from the gel. Therefore, during the last years, 
many efforts were oriented to build-up gel-free methods to analyse proteolytic 
mixtures without an upstream protein separation step. The analysis of complex 
peptide mixtures by means of HPLC-MS is known as “shotgun proteomics” or 
MuDPIT (Multi-Dimensional Protein Identification Technology)[20]. The 
protein sample is directly subjected to proteolytic digestion, usually with two 
(or more) different enzymes (typically Lys-C and trypsin), and the obtained 
peptide mixture is subjected to a two-dimensional liquid chromatography 
separation (2D-LC)[21,22]. 2D-LC exploits two serial orthogonal dimensions of 
separation to resolve complex peptide mixtures with high efficiency, thus 
improving the dynamic range of the MS identifications. The second dimension 
is usually a reversed-phase LC (RP-LC) step, because of its efficient 
separation power and the employment of salt-free MS compatible solvents[23] . 
The first chromatographic dimension takes advantage of a different principle, 
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such as strong cation exchange (SCX)[24,25], strong anion exchange (SAX)[26], 
hydrophilic interaction liquid chromatography (HILIC)[27,28], and in gel or in 
solution isoelectric focusing (Offgel)[29,30].  
Peptides are finally analysed by mean of mass spectrometry. The peptide 
identification comes in two different ways: the so called peptide mass 
fingerprint (PMF) and tandem MS profiling[31,32]. Basically, in the former 
approach, the identity of unknown proteins is revealed by matching the 
measured peptide masses against a database of theoretical proteolytic 
fragments originated from in silico protein digestions. This approach is 
suitable for simple protein mixtures, such as digested spots coming from a 2D-
PAGE. However, even though modern mass spectrometers have a ultra-high 
resolution and mass accuracy of a few ppm, the effectiveness of PMF analysis 
is inadequate because it is based only on the mass of the intact peptides. 
Therefore, the more informative tandem MS experiments are becoming 
widespread. Tandem MS relies on the employment of instruments equipped 
with an appropriate fragmentation source to record both the masses of the 
intact peptides and the originated fragments. The measurement of the daughter 
ions is useful to retrieve the true peptide sequence; indeed, depending on the 
fragmentation technique, the identity of the generated fragments is predictable. 
The most common and robust fragmentation technique is the so called 
collision induced dissociation (CID)[33]; also electron transfer dissociation 
(ETD)[34,35] and high collision dissociation (HCD) are very informative and 
can be employed alternatively to gain more informations on peptide 
sequences. More in details, CID exploits an inert gas such as nitrogen, argon 
or helium to induce the peptide fragmentation in a “mild” fashion, causing the 
amide bond (mostly y and b ions are produced) breakage[36]. On the contrary, 
ECD/ETD induces random fragmentation along the peptide backbone, even if 
c and z ions are mostly formed employing thermal electrons or fluoranthene as 
source of energy[37,38]. Finally, HCD[39] is a beam based fragmentation 
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technique mainly employed in the isobaric tag–based quantification (see 
global proteomics paragraph)[40,41]. CID, ETD and HCD are considered as 
complementary techniques, since CID is well suited for the fragmentation of 
doubly and triply charged peptides, whereas ETD is preferred for the  
fragmentation of peptides with higher charge, with internal basic residues and 
for the analysis of post-translational modifications. Therefore, the application 
of a “decision tree” in which the fragmentation source is decided “on the fly” 
by the mass spectrometer, based on the precursor ion characteristics, has been 
demonstrated to be effective to improve the identification capabilities[42]. 
Once the full MS and the MSMS spectra have been generated, the empirical 
fragmentation peptide profiles are matched with theoretical ones, contained in 
web accessible databases (SwissProt, NCBInr), through a number of different 
search engines and algorithms, among which MASCOT[43] and SEQUEST[44] 
are the most used. 
 
 
1.2 Global Proteomics  
 
Mass spectrometry has emerged as one of the main tools for large-scale 
protein analysis, due to its unbiased nature and conceptual simplicity. Several 
cellular pathways can be modulated upon drug treatment, leading to a change 
in the level of specific subsets of proteins, so the drug-induced response is of 
central importance to understand the pathways involved in the final 
pharmacological and toxicological effects[45-47]. 
Mass spectrometry-based proteomic analysis provides the possibility to 
estimate the entire proteome alterations in a single experiment[48].  
Many global proteomics strategies are today available to evaluate the response 
of a whole proteome to external stimuli and can be distinguished in gel-based 
and gel-free approaches (Figure 2). 
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Gel-based approaches are built on the evaluation of the intensities of the 
protein spots in a 2D-PAGE run, since they are directly proportional to the 
protein amounts. Proteins from two (or more) different samples (eg. 
chemically treated and un-treated cells) are separated on the basis of their pI 
and molecular weight and then stained as described in paragraph 1. The 
intensity of each spot is quantified and compared by means of a differential gel 
image analysis. Up- or down-regulated proteins are finally in situ digested  and 
identified by MALDI-MS or LC-MSMS. 
  
 
Figure 2. Schematic workflow of global proteomic experiments. 
 
2D-PAGE, although suffering from some shortcomings, as discussed below,  
is a consolidate technique largely employed in global proteomics profiling, 
mainly due to its high resolving power[49].  
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To improve its efficiency, the so called two-dimensional differential in gel 
electrophoresis (2D-DIGE) is now routinely employed. In a 2D-DIGE 
experiment, samples are pre-labelled with fluorescent dyes (called Cy2, Cy3 
and Cy5) and then mixed prior to isoelectric focusing, and therefore up to 
three samples can be run on the same gel[50,51]. After completion of the 
electrophoresis run, the gel is scanned at the different excitation wavelengths 
of each dye, providing three gel images. Then, the images are superimposed, 
spot margins are defined and volumes are calculated and compared, giving the 
accurate protein expression levels for each sample. CyDye technology has an 
higher degree of linearity compared to silver and coomassie blue stains and is 
also quicker and more sensitive[52].  
Although the introduction of DIGE technique has overcome some of the 
shortcomings limiting the application of classical 2D-PAGE[53],  mainly due to 
“gel-to-gel” variations, both approaches are still affected by some restrictions 
imposed by the use of the gel procedure. First of all, the analysis is often 
complicated by co-migration of various proteins in a single spot or, on the 
contrary, by the presence of the same protein in multiple spots, due to isoforms 
and post-translational modifications. Furthermore, extremely acidic, basic or 
hydrophobic proteins (e.g. membrane-bound proteins)[54], low and very high 
molecular weight or less abundant proteins[55] are hardly monitored.  
The drawbacks affecting gel-based approaches, together with the tremendous 
developments of mass-spectrometric performances and LC-based separation 
techniques, led to a rapid spread of gel-free approaches. Gel-free methods can 
be further divided in label-based and label-free approaches.  
The label-based methodologies rely on the use of “labelled tags” to distinguish 
the same analyte in different samples within a single LC-MS experiment. 
During the last years, a number of labelling methods have been developed, 
grouped in metabolic and chemical labelling approaches (Figure 3). 
 
   Introduction 
- 13 - 
 
Figure 3.  Most common label-based quantization techniques 
 
In the metabolic approach,  the label is introduced in vivo through auxotrophic 
amino acids[56]. More in details, this labelling technique, known as Stable 
Isotope Labelling by Amino acids in Cell culture (SILAC), relies on the ability 
of cells fed with heavy amino acid  to capture and incorporate them in the 
newly synthesized proteins[57]. Therefore, two cell populations are cultivated 
either in presence of natural or isotopically (e.g. with deuterium, 13C, 15N)[58,59]  
labelled amino acids and, after a number of cell divisions, one population is 
treated with the drug. Both the treated and un-treated cells are finally lysed 
and the extracted proteins are mixed prior to protein digestion. Due to the high 
complexity of the samples, usually the enzymatic digestion is performed by 
means of two different proteolytic enzymes, typically Lys-C and trypsin, and 
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the mixture is subjected to a two-dimensional liquid chromatography 
separation (2D-LC). The following MS analysis allows the comparison of the 
peptides coming from the two samples connected by the mass-shift signature 
due to the incorporated tags and, through specific bioinformatics tools, the 
differentially expressed protein can be identified and quantified. 
Chemical labelling approaches (Table 1) exploit chemical reaction to insert 
the tag portion either at protein or peptide level. The most common techniques 
are the isotope coated affinity tag (ICAT)[60], iTRAQ[61], and dimethyl 
labeling[62]. 
The initial ICAT reagent has a iodoacetyl group tethered to a biotin tag via a 
deuterated or non-deuterated oxyethylene linker. The iodoacetyl moiety reacts 
with the cysteine side chain whereas the biotin portion is required for the 
affinity isolation step. Samples to be compared are treated either with the light 
probe (d0) or with the heavy one (d8). Once the two protein samples have 
been marked, they can be mixed and subjected to protein digestion. Prior to 
LC-MS analysis, tagged peptides are enriched by means of the biotin-avidin 
affinity (on coated column). The isolated peptides are finally analysed as 
already described for SILAC (Figure 3)[60].    
Both SILAC and ICAT allow the comparison of up to two samples in one 
experiment, whereas iTRAQ has been developed in a multiplexed fashion and 
allows the simultaneous analysis of up to eight  samples. 
The iTRAQ reagent consists of three fundamental building blocks: a 
quantification group (N-methylpiperazine), a balance group, and a hydroxyl 
succinimide ester group that reacts with the N-terminal amino groups and ε-
side chain of lysines. The reactivity of iTRAQ reagents is conceptually more 
convenient than the ICAT reagent, since each ion selected for fragmentation 
contributes to the abundance estimation. Nevertheless, the most important 
difference between iTRAQ and the other techniques is that the quantification 
occurs at the MS/MS rather than MS level (Figure 3). This opportunity gives 
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a higher signal/noise ratio, due to the reduced chemical noise in MS2, and a 
gain in sensitivity due to the isobaricity of the tags.  
To date, eight iTRAQ reagents are commercially available, each having stable 
isotopes that are uniquely distributed between the reporter groups (m/z: 113, 
114, 115, 116, 117, 118, 119, and 121) and the balance group. When iTRAQ-
modified peptides are analysed by MS/MS, the signal intensity ratios of the 
reporter groups reflect the peptide quantities among different samples.  
Nevertheless, precursor contamination results in under-estimation of small 
changes[63,64] and, additionally, the cost of the iTRAQ reagents and the request 
of a mass spectrometer equipped with the opportune fragmentation source able 
to produce MS/MS fragments at low m/z, such as HCD,  limit the use of this 
technique. 
 
Table 1. Structures of isotopic labels for SILAC, ICAT, iTRAQ and dimethyl labeling. 
 
Another label-based quantification technique that is worth to be mentioned, 
because of its low cost and massive applicability, is the so-called stable 
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isotope dimethyl labeling[65,66]. Peptide N-termini and lysine ε-amino groups 
quickly react with formaldehyde and cyanoborohydride producing N,N-
dimethyl-amine peptides with a mass increment of 28 Da[67]. Using deuterated 
formaldehyde, an isotopically marked peptide is obtained with a mass 
increment of 32 Da, whereas treating peptides with 13C-(d2)-formaldehyde and 
cyanoborodeuteride, a mass increment of 36 Da is obtained (Figure 4). The 
quantification step is achieved comparing the intensities of the peptides 
matching the particular mass shift patterns due to the different labelling.  
 
 
 
Figure 4. Triplex stable isotope dimethyl labeling 
 
Isotopically and gel-based techniques are to date crucial tools to compare 
biological samples by mass spectrometry. Nonetheless, label-free methods are 
acquiring a growing importance in quantitative-MS field. The main 
advantages of label free methods are the virtual no-limit number of samples 
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that can be compared, and the higher dynamic range of quantification[68,69]. In 
label-free quantification approaches, each sample is separately prepared and 
then subjected to LC-MS/MS[70]. The relative or absolute protein quantity is 
then deduced either from the intensity of the intact proteolytic peptides, or by 
counting and comparing the number of MSMS spectra. The former method is 
based on the linear correlation between sample concentration and the signal 
response produced by electrospray ionization (ESI)[71]. Peak area integration 
of a set of peptides per protein yields relative quantitative information among 
multiple samples. This method requires a fine tuning of chromatographic and 
mass spectrometric conditions. Indeed, the equivalent chromatographic 
profiles enable an easier alignment of two or more runs, that is needed to 
compare peptide intensities in different experiments. Finally, a right balance 
between acquisition of survey and fragment spectra (needed for peptide 
identification) is necessary to improve the peak area integration without 
compromise protein identification. Generally, this last issue is particularly 
difficult to accomplish and often a double run is required, in which the protein 
identification and quantification steps are performed in two consecutive steps.  
This procedure is tedious and sample-consuming, even if more accurate.  
The quantification procedure based on the count of MS/MS spectra is 
becoming more popular. In a data dependent scanning, the number of MS/MS 
spectra generated per peptide is actually connected to its abundance. The count 
and comparison of the generated MS2 spectra allow the relative quantification 
of each identified protein. 
  
 
1.3 Activity based protein profiling 
 
Global proteomic methods record variations in the protein abundance, 
providing an indirect estimation of changes in protein activity. Actually, 
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changes in protein abundance represent only a small part of the factors that 
influence the activity of enzymes: indeed, post-translational modifications, 
proteolytic processing, protein-protein interactions play a central role in 
enzyme activity regulation[72]. Activity-based protein profiling (ABPP) has 
become an important tool in proteomics and, in turn, in chemical biology 
research due to its ability to monitor the active enzymes. On this basis, this 
technique is apart from the global proteomics approaches, whose first aim is 
profiling proteins on the basis of expression and abundance.   
Activity based protein profiling (ABPP) uses active site-directed chemical 
probes to assess the functional state of  specific subsets of enzymes in their 
native biological environment. ABPP probes are composed at least by three 
fundamental building blocks: (i) a reactive group, useful to bind and 
covalently label the active sites of a given enzyme class (warhead), (ii) a 
reporter tag, needed for the detection, enrichment and identification of probe 
labelled proteome and (iii) a linker spacer (Figure 5).  
 
 
 
 
Figure 5. Schematic representation of probe key features with some representative examples. 
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ABPP probes are designed to monitor a large number of enzymes without 
cross-reaction with other proteins in the proteome, thus they take advantage 
from the structural features that characterize the active sites of different 
enzyme classes[73]. On the basis of the labelling mode, three main classes of 
probes can be distinguished: (i) general alkylating probes, (ii) activity-based 
probes (ABPs) and (iii) affinity-based probes (AfBPs) (Figure 6). The first are 
based on the intrinsic capability of some functional groups to covalently label 
amino acids  residues, such as cysteine, in a non-specific manner. On the 
contrary, ABPs are mechanism-based or suicide inhibitors tailored on the 
catalytic active site of the enzyme[74]. The reaction mechanism responsible for 
the labelling event involves amino acid residues normally responsible for the 
binding of the natural substrates. Most of the functional reactive groups of the 
probe are represented by electrophilic traps such as epoxides or Michael 
acceptors (Figure 5). The reactive portion of the probe can be also “masked” 
in the original molecule and can be converted by the target enzyme in the 
reactive form. One of the main advantage of this kind of probes is their ability 
to bind the enzyme in a mechanism-based fashion enabling, as a consequence, 
only the visualization of enzymes in the active state. On the other hand, the 
ABPs design requires a deep knowledge of the catalytic mechanism of the 
active enzymes, precluding the investigation of less studied enzyme classes. 
Affinity-based probes greatly overcome this limitation recognizing the enzyme 
and performing a non-specific binding of a nearby protein functional group, 
not necessary involved in the catalytic mechanism. The bond formation can be 
a spontaneous event but is usually achieved by a photoreactive cross-linker, 
such as benzophenone or diazirine, that covalently binds the target enzymes 
upon UV irradiation[75]. Although AfBPs have been successfully applied to 
label the metallo-protease enzyme family and the HDACs[76-80], ABPs are still 
the most common probes in enzyme profiling. 
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Figure 6. Three main classes of probes distinguishable on the basis of labelling mode 
 
The tag portion of the probe allows the visualization and identification of the 
labelled proteins. The most commonly used tags are biotin, fluorophores, 
epitope or radioactive tags,  that are compatible with the proteomic analysis 
systems such as SDS-PAGE, western blotting or liquid chromatography 
coupled to mass spectrometry. Gel-based approaches are preferred for a rapid 
comparative analysis of several proteomes. Probe-treated proteomes are first 
resolved by one or two-dimensional polyacrylamide gel electrophoresis (1D or 
2D SDS-PAGE), and then visualized by either in-gel fluorescence scanning or 
avidin blotting[81,82].  
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Currently, biotin probes are largely employed because biotinylated proteins 
can be easily enriched by avidin-beads. The biotin-avidin interaction is very 
strong, nearly irreversible (KD=10-15 M), thus also low abundant proteins can 
be efficiently isolated. Moreover, enriched proteins can be manipulated and 
identified by means of different proteomics techniques. Indeed, the bound 
proteins can be eluted by a denaturing buffer, separated by SDS-PAGE and 
subsequently subjected to in gel digestion for LC-MS/MS analysis[83,84]. 
Alternatively, proteins can be directly subjected to on-beads digestion and 
analysed by multidimensional LC-MS/MS (ABPP-MudPIT). Taking into 
account parameters such as spectral counts or by means of other quantification 
strategies (SILAC or ICAT), it is also possible to compare the amount of 
active enzymes in two or more proteomes[84-88]. Although the advantages of 
this technique, some shortcomings needs to be highlighted. Contamination by 
avidin and endogenously biotinylated proteins can be significant, and in many 
cases would prevent detection of low abundance targets. Furthermore, the on-
bead digestion method leads to significant false positives, as a result of non-
specific protein binding to the avidin resin.  
Another LC-MS platform termed active-site peptide profiling (ASPP) is worth 
to be mentioned. The probe-labelled proteins can be digested in solution prior 
to an affinity enrichment, allowing the identification of modified peptides and, 
as a consequence, giving important information about the enzyme active 
site[88,89].  
The warhead is often linked to the tag region through a linker spacer that, 
providing enough space between the two components, facilitates both the 
reaction of the functional group with the enzyme and the purification step.  
The linker region can range from an alkyl group to a PEG spacer or a peptide 
chain, and can incorporate a specific element to assist the recognition of the 
enzyme[90]. 
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Additionally,  linkers incorporating cleavable sites between the biotin and the 
bound biomolecule, such as proteolytic[91] and chemically labile[92-94] groups 
have been reported. These cleavable sites allow the release of the probe-
labelled enzyme in mild conditions, enabling manipulation of the 
biomolecules in their native state. 
To date, probes have been developed for more than a dozen of enzyme classes, 
including proteases, kinases, phosphatases, glycosidases, and oxidoreductases, 
and a wide range of chemical scaffold have been employed for probe 
design[74]. The achievement of selectivity requires the tuning of both the probe 
affinity and reactivity. In fact, highly reactive warheads tend to be 
promiscuous, thus it is necessary to consider the enzyme chemistry or include 
a specificity element that directs the ABP to a particular class of enzymes or to 
a specific enzyme within a class. Chemical modification enables the reactivity 
to be confined and the probes optimized according to the requirements of 
specific target enzyme classes[95]. Multiple biological methodologies for ABPP 
technology have emerged, and among them (i) comparative ABPP for target 
discovery, (ii) competitive ABPP for inhibitor discovery, and (ii) in vivo 
imaging. (Figure 7).  
The first approach exploits the comparison of two or more proteomes in 
different physio-pathological conditions by ABPP to identify  enzymes whose 
activity is regulated in response to external stimuli. Enzymes with unknown 
role can be visualized in a comparative experiments, thus they may be 
assigned to a specific mechanistic class on the basis of their ability to react 
with specific ABPs[96].  
The second major application of ABPP is the discovery of enzyme inhibitors. 
Inhibitor discovery by ABPP is possible because small molecules can compete 
with the activity-based probes for the binding to the enzyme active sites, 
thereby slowing the rate of probe labelling. The library of candidates inhibitors 
is pre-incubated with a cell or tissue-derived proteome and then the mixture is 
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treated with ABPs. Inhibitor-sensitive enzymes are detected by a reduction in 
probe labelling intensity. 
 
 
Figure 7. Main applications of ABPP in chemical biology research. 
 
Competitive ABPP has several advantages over classical substrate assays for 
inhibitor discovery. First, the screening is realized directly in complex 
proteomes, thus there is no need to express and purify enzymes. Moreover, 
since the library is screened against several enzymes in parallel, promiscuous 
agents can be discarded in favour of selective compounds[97] .  
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Another remarkable application of ABPP in chemical biology is represented 
by the employment of fluorogenic probes for enzyme labelling and 
localization in vivo by microscopy and whole organism imaging. Bogyo’s 
group pioneered this field unravelling the potential of ABPP toward 
applications in tumour imaging, by exploiting caspase directed ABPs[98].  
Since ABPP plays a key role in chemical biology research, several strategies 
have emerged for a broader applicability of this technique. Particularly, there 
is a pressing need of tools to measure the levels and activities of biomolecules 
directly in cells, tissues, and fluids. In fact, assessment of the functional state 
of proteins in biological samples requires proteins in their native (functional) 
state, but some proteins may not tolerate the transfer from the cellular context 
to a cellular lysate, and only a minority of full probes has been reported to be 
permeable[99]. In this scenario, the bio-orthogonal chemistry, or click 
chemistry, has demonstrated to be able to overcome two of the main 
limitations of ABPP, that are the interference of bulky tags on enzyme 
recognition and the ineffective application of traditional ABPP in cellular 
context.  
Bio-orthogonal chemistry is based on the design of warheads decorated with a 
functional group unable to react with biomolecules, but highly reactive with an 
orthogonally-functionalized reporter tag (Figure 8). The presence of this 
“latent chemical handle”, instead of a bound tag, allows the introduction of the 
visualization/identification tag in a second step, after the bound-forming event 
between the enzymes and the warhead[100]. To be employed in this field, 
organic reactions need to proceed in aqueous buffer, under mild conditions 
and rapidly yielding a single desired product. Moreover, both counterparts 
must be absolutely inert to biological molecules. The Staudinger-Bertozzi 
reaction is the first example of chemistry applied to bio-orthogonal ligation 
and was developed by the Bertozzi’s group on the basis of the classic 
Staudinger reaction of azides with triarylphosphines[101]. 
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Figure 8. Schematic representation of most common bio-orthogonal reactions in ABPP 
 
The first step of this reaction is the nucleophilic attack of the phosphine at the 
electrophilic terminal nitrogen of the azide. Through nitrogen loss, an unstable 
aza-ylide is formed and rapidly hydrolyzed by a water molecule. To improve 
the kinetics and the bio-orthogonality, Bertozzi’s group included an 
electrophilic trap, a methyl ester, on the triaryl phosphine. The Staudinger-
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Bertozzi ligation has been used both in living cells and mice, but currently it is 
no longer widely applied because the reaction is too slow for bio-conjugation 
purposes[102]. 
An extremely fast and effective reaction for bio-conjugation is the copper(I) 
catalyzed variant of the Huisgen 1,3-dipolar cycloaddition (click reaction). 
Both the azide and terminal alkyne are compatible with biological samples and 
give rise to the specific formation of 1,2,3-triazoles in aqueous buffers, 
without cross-reactions with biomolecules[103-105]. In recent years, a wide and 
rapidly growing number of copper-free click reactions have been developed to 
remove the need of copper.  In these settings, the azide-alkyne cycloaddition 
progresses in a so called “strain prompted” way, thanks to the high reactivity 
of cyclooctynes[106]. 
 
 
1.4 Compound centric chemical proteomics 
 
As already mentioned, targets identification of bioactive small molecules is 
today considered one of the main issues for the clarification of their molecular 
mechanism of action[107-109]. Drugs, natural products and toxins explicate their 
activity through the interaction with biological macromolecules, mostly 
proteins, forming transient or stable complexes which in turn mediate 
biological responses[110]. Both academic and pharmaceutical research spend 
many efforts to design selective drug candidates that inhibit efficiently one or 
a few target(s) without cross-react with other cellular enzymes/proteins, 
minimizing the undesired side effects. The compound selectivity is usually 
assessed by testing its effects on a panel of purified enzymes, selected as 
putative additional targets[111-113]. Nevertheless, these in vitro assays often 
produce partial results because the panel of proteins is obviously limited and 
do not include unexpected drug targets. Furthermore, the method is tedious, 
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expensive and the capability of small molecules to target and modulate 
numerous pathways shouldn’t be considered a priori as a negative feature, 
since multi-target drugs may exert an high clinical response[114]. Therefore, 
during the past years, a number of alternative strategies have been developed, 
such as chemical-genetic profiling in yeast, yeast three-hybrid system, 
transcriptional “signature” analysis, and affinity chromatography on 
immobilized drugs[115,116].  
Among them, an affinity purification mass spectrometry based technique (AP-
MS) has emerged as a valuable and unbiased mean to link bioactive 
compounds to their cellular targets[117-120]. This technique, also known as 
Compound Centric Chemical Proteomics (CCCP), Capture Compound Mass 
Spectrometry (CCMS) or Affinity Based Chemical Proteomics (ABCP), relies 
on the capability of a small molecule, anchored to a solid support, to “fish out” 
from a protein extract its macromolecular targets, then identified by LC-
MSMS[121].  
This technique consists of three main steps: (i) chemical immobilization of the 
small molecule onto a solid support; (ii) affinity enrichment of the 
compound’s cellular partners from a protein mixture; (iii) elution and 
identification of the captured proteins by means of mass spectrometry coupled 
to bio-informatics (Figure 10).  
To be used as a bait, the small molecule has to be immobilized on an inert 
solid support[122,123] (eg. Silica or agarose) (Figure 9), therefore the presence 
of a suitable reactive functional group (usually an amine, carboxyl, hydroxyl, 
or sulfhydryl group) is a fundamental requirement; alternatively, a proper 
functionalized analogue can be synthesized,  as long as the original biological 
activity is retained[9].  
Usually, the small molecule is not directly immobilized onto the solid support 
surface, but the matrix is rather modified by a spacer arm that, providing 
enough space between the beads and the molecule, avoids a potential steric 
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hindrance promoting the interactions between the compound and its 
macromolecular partners[124-126] (Figure 10).  
 
 
 
 
Figure 9.  Schematic representation of matrix and linkers. 
 
Linkers used as spacers may have different lengths and hydrophilicities: 
however, too much long spacers arms (more than 15 atoms) are not preferred 
because self-interactions can cause their auto-aggregation in aqueous 
solutions. Moreover, the use of hydrophilic linkers is useful to facilitate the 
removal of low affinity interactions established between the linker and 
proteins[126]. Long-chain alkyl or polyethylene glycol (PEG) spacers respond 
to the required characteristics and are usually employed. Emerging spacer 
arms incorporating cleavable sites have been also proposed[127,128] (Figure 9) 
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to selectively retain the proteins captured by the molecule, eliminating the 
amount of unspecific binders fished out by the solid supports. 
Once the small molecule has been immobilized, the functionalized  support 
can be  incubated with the protein mixture. Cells, tissues or serum can be used 
as source of proteins, as long as the protein extraction and their incubation 
with the bait are performed in mild conditions to preserve the native state of 
proteins. After the incubation, the beads are subjected to abundant washings 
with a saline buffer to reduce the amount of proteins un-specifically adsorbed. 
Strictly bound proteins are finally eluted by using denaturing buffers, often 
containing SDS (Figure 10).  
 
 
Figure 10. Schematic workflow of CCCP strategy. 
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Proteins eluted from the bait are then separated by means of SDS-PAGE and, 
after excision from the gel, the bands are subjected to in situ digestion and the 
proteins are identified through nanoLC/MSMS coupled to bio-informatics 
analysis.  
Like any other technique, chemical proteomics has strengths and weaknesses 
(Figure 11). As already mentioned, the main advantage of CCCP is the 
pseudo-physiologic environment in which the interactions occur. In this 
setting, the normal abundance of proteins, the presence of natural cofactors 
and physiological post translational modification are maintained, guaranteeing 
a more realistic picture of the small molecule interaction profile. Nevertheless, 
the protein extraction procedure is often unable to capture all the cellular 
proteins because of their different solubility profile[9], as in the case of 
membrane proteins. Moreover, lysis conditions could compromise also the 
intactness of physiological multi-protein complexes, which are the real cellular 
functional units[130]. To address this issue, as extensively described in the 
previous paragraph, new strategies based on the bio-orthogonal chemistry are 
emerging to let the interactions between the proteins and bait occur into the 
cellular environment.   
The immobilization of the molecule onto a solid support is also a critical point 
of the technique. As already mentioned, it could be desirable to verify that the 
chemical modification does not perturb the biological activity of the 
compound. Furthermore, when a molecule is immobilized onto a solid matrix, 
the interactions occur at the interface between the solid and liquid phase; this 
issue is partially accomplished by the employment of spacers arms to 
minimize the steric hindrance due to the matrix[126]. As a valuable alternative 
to solid supports, linkers containing a biotin portion are also employed. The 
biotin-linked molecule targets its partners in solution, and later on it is 
captured by affinity  on avidin columns[131,132]. 
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One of the main drawbacks of these procedures is the residual amount of non-
specific proteins that are not completely removed through washings, 
generating false positives. On this basis, a number of approaches have been 
introduced to distinguish between specific and un-specific interactors. The 
simplest method consists in performing a control experiment, incubating the 
protein mixture with un-derivatized beads; proteins identified in the control 
experiment are considered as background and discarded[114]. Although this 
method has been largely used, false negative can be generated. In fact, some 
proteins may be true drug-interactor, although they also binds to the solid 
matrix. Above all, highly abundant proteins may give false negative results 
due to the high likelihood of their interaction with the solid support[133]. 
Quantitative methods have been also introduced to overcome the false 
negative issue. Samples coming from the drug and control experiments can be 
tagged and quantified through the already mentioned methods: isotope-coded 
affinity tag (ICAT)[134], isobaric tags for relative and absolute quantification 
(iTRAQ)[135], dimethyl labelling (see paragraph 1) and stable isotope labelling 
by amino acids in cell culture (SILAC)[136]. Proteins enriched from the bait are 
distinguished from background not merely on their absence in the control 
experiment, but rather comparing their quantitative (relative) abundance ratio. 
The main advantage to perform a control experiment with empty beads is its 
ability to simplify the research of the physiological relevant drug-interactors, 
“cleaning up” the list of the identified proteins from “sticky” and abundant 
proteins. However, most of the proteins fished out from the bait are actually 
true interactors that binds the small molecule with low affinity. Since these 
kind of low affinity interactions are unlike to be physiological relevant, further 
experiments are usually required to recognize significant, high affinity 
interactions.  
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Figure 11. Principal advantages and disadvantages of CCCP tecnique with most common 
strategies proposed to overcame shortcamings. 
 
Among the possible approaches, the best should be the employment of control 
beads bearing a structural analogue of the investigated compound lacking its 
biological activity. However, this option  is not easy to realize, because often 
the information on the drug biological activity are lacking or, in the case of 
natural compounds, their synthesis is particularly laborious.   
Another procedure to bona fide recognize the specific interacting proteins is 
their competitive elution from the solid support, using the free compound in 
solution (Figure 12)[125]. In some details, after the affinity chromatography 
experiment, an aqueous solution of the free ligand is added to the beads, 
enabling the release of the specific drug-partners. Since the effectiveness of 
this method can be affected by the slow dissociation kinetics of the specific 
binding protein(s), in an alternative experimental design, the free ligand is 
added to the protein mixture before the affinity step. If the affinity enrichment 
is performed in the presence or absence of the free compound, the following 
eluted target can be recognized by their different intensity in the gel runs. This 
approach has some limitations, in particular when compounds have low 
solubility in aqueous buffer. An alternative procedure, called serial affinity 
chromatography strategy, has been described[125]. After the affinity 
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enrichment, the unbound proteins are not discarded but added to a fresh 
aliquot of the ligand-bearing resin (Figure 12). Non-specific background 
proteins can be recognized by their ability to equally bind to each matrix 
sample, whereas specific target(s), almost totally fished out by the first batch, 
should disappear.  
 
 
Figure 12. Competitive and Serial Affinity Chromatography 
 
The application of CCCP to the analysis of small molecules interactome has a 
high potential,  mainly due to its unbiased nature. Deconvolution of the raw 
results by employment of one or more of the above-mentioned filter 
techniques often drives to a short list of drug-target candidates, that are very 
likely to be physiologically significant[117-119]. Without any doubts, further 
 
Introduction 
 
 
- 34 - 
 
investigations are usually required to validate and to deepen the nature and the 
relevance of the identified interactions.  First of all, techniques as SPR, ITC or 
Alpha Screen can be used to quantify the affinity of the interaction between 
the compound and the identified partner(s) (Figure 13). When possible, also 
STD-NMR and co-crystallization can be applied,  due to their informative 
results.  
 
Figure 13. Most common techniques employed to validate and quantify ligand-protein 
affinity. 
 
Moreover, in vitro or in vivo biological assays may be employed to investigate 
the capability of the small molecule to modulate its partner(s) in a purified or 
biological environment, respectively. 
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1.5 Aim of the research project 
 
Bioactive small molecules exert their activity through a specific interaction 
with biological macromolecules. One of key point in the drug discovery and 
development process is the identification of the interactome of new lead 
compounds, that is essential to characterize their molecular mechanism of 
action[107-109].  
The natural environment, particularly marine ecosystem[137], represent a rich 
source of secondary metabolites often endowed with intriguing chemical 
structures and biological activities. A comprehensive account of their 
interactome can be achieved by means of chemical proteomics approaches, 
thus enlightening the potentialities of  these small molecules as new lead 
compounds and defining their target and off-target activities.  
In this scenario, this research project aimed the analysis of the in vitro 
interactome of some small bioactive molecules extracted from marine sources 
by means of compound centric chemical proteomic techniques.  
Moreover, a chemical proteomic investigation inside a living cell 
compartment, based on the application of bio-orthogonal chemistry, has been 
developed and then compared with the classical in vitro procedure.  
The project has been completed by the study of the interaction profile of the 
endogenous cyclic nucleotide cCMP, during a training experience at the 
Utrecht University,  under the supervision of Prof. Albert J. Heck. 
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Chemical Proteomics Reveals Heat Shock Protein 60 as the 
Main Cellular Target of the Marine Bioactive Sesterterpene 
Suvanine 
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2.1 Background 
 
Through the process of natural selection natural products have acquired a huge 
chemical diversity, responsible for their unique biological properties, as they 
have evolved for optimal interactions with biological macromolecules.  
Thus, natural products have proven to be one of the richest source of novel 
structural classes for biological studies and an essential supply for the 
discovery of new drugs. Particularly rich is the marine environment and is a 
wealthy source of plants, animals, and micro-organisms that, because of their 
adaptation to this unique habitat, produce a wide variety of secondary 
metabolites[137]. Some of them are approaching phase II/III clinical trials for 
the treatment of cancer, algesia, allergy, cognitive and inflammatory 
diseases[138,139]. 
The identification of the cellular interactome of these natural compounds is 
crucial to define their specific mechanisms of action and to understand their 
pharmacological effects[119,122].  
Suvanine (SUV) is a tricyclic bioactive sesterterpene, first recovered in the 
MeOH extract of the sponge Coscinoderma mathewsi Lendenfield (order 
Dictyoceratida, family Spongiidae), collected at Pohnpei, Micronesia, during a 
wide screening of marine sponge based on the discovery of thrombin and 
trypsin inhibitors[140]. Later, SUV was also found in the ethanolic extract of a 
different specimen of the same sponge, collected off the coasts of Solomon 
Islands, showing an interesting anti-inflammatory activity[141]. Research into 
new bioactive metabolites from marine sponges of the Coscinoderma genus is 
of interest because these animals contain sulphated terpenoids that often 
exhibit valuable biological effects. For example, halisulfate 7 is an inhibitor of 
the catalytic subunits of the mammalian Ser/Thr protein phosphatase 
calcineurin[142], while halisulfate 1 is a potent isocitrate lyase inhibitor, and 
coscinosulfate displays significant inhibitory activity towards CDC25A 
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phosphatase[142–145]. Preliminary pharmacological studies demonstrated the in 
vitro inhibition by SUV and its derivatives of different secretory 
phospholipases (sPLA2), NO and prostaglandin E2 (PGE2) production[141].  
However, the bio-molecular targets and the mechanisms of action responsible 
for the interesting properties of SUV were not yet defined and  represented an 
interesting task to be solved. To reach this goal, a MS-based affinity 
chromatography approach has been applied to fish out the biological target(s) 
of SUV from HeLa cells. 
 
 
2.2 Generation of Suvanine functional matrix 
 
The first step in a chemical proteomic experiment is the immobilization of the 
small molecule onto the surface of an appropriate solid support, to allow the 
recovery and MS-based  identification of proteins selected during the affinity 
chromatography step. The presence of a proper reactive group in the 
compound structure is hence required. 
SUV (Figure 14) does not contain a functional group suitable for its 
immobilization, thus a semi-synthetic transformation was needed. We planned 
the desulfatation of SUV to obtain its aldehyde derivative that, besides an 
higher reactivity, retains the anti-infiammatory activity of the natural 
compound[141]. The aldehyde containing derivative (SUV-AL) was obtained, 
as demonstrated  by MS analysis and NMR characterization[121], by incubating 
the natural compound at 150°C in a mixture of pyridine and dioxane for 2.5h 
(Figure 14). 
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Figure 14. Hydrolytic transformation of Suvanine to its aldehyde derivate and ESI-MS 
spectrum 
 
As extensively discussed in Chapter 1, the insertion of an appropriate spacer 
arm between the small molecule and the matrix is particularly advantageous. 
Thus, on the basis of our previous studies[117–119], we chose 4,7,10-
trioxatridecane-1,13-diamine (NH2(PEG)3NH2) as linker. Its reactivity with 
SUV-AL was analysed by a preliminary LC-MS investigation. The reaction 
was performed in ACN/NaHCO3 and, after 2h at r.t., NaBH4 was  added to the 
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mixture to reduce the Schiff base formed by nucleophilic attack of the linker 
terminal amino group onto the SUV-AL carbonyl aldehyde (Figure 15). A 
main peak at m/z 575.8 Th, consistent with the postulated reaction adduct 
formation, was actually visible after 30 minutes of reduction (Figure 16). 
 
 
 
 
 
Figure 15. Reaction pathway between SUV-AL and NH2-PEG3-NH2 in presence of NaBH4 
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Figure 16. MS spectrum of the ion at 575.8 Th and its fragmentation pathway 
 
Although the synthesized adduct, containing a free amino group, could be 
directly immobilized onto the carbonyldiimidazole activated beads, in order to 
optimize the total reaction yield and avoid the formation of a dimeric by-
product, observed during the reaction of two SUV-AL molecules with the 
linker, we preferred to functionalize in a first step the beads with the di-amino 
linker and then anchor SUV-AL on the solid support (Figure 17). To verify 
the effectiveness of the first reaction, a Kaiser test was carried out, confirming 
the presence of free amino groups onto the beads surface. Subsequently, SUV-
AL was added to the mixture and the reaction monitored by RP-HPLC-UV. 
Comparing the peaks of SUV-AL before and after 16 h of reaction, a  yield of 
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~50% was assessed and a final concentration of 0.01 mmol of SUV-AL  per 
mL resin was estimated. The coupling process was completed by acetylation 
of the residual unreacted free amino groups. 
Finally, as a control matrix (CTR-Matrix) (see Chapter 1 and next paragraph), 
a batch of linker-bearing resin was subjected to acetylation as reported in 
Figure 17. 
 
 
  
Figure 17. Preparation of SUV functionalized beads and control beads 
 
 
2.2 Affinity purification and identification of suvanine partners  
 
Samples of SUV-bearing matrix and the control matrix were separately 
incubated with the crude extracts of HeLa cells, to let the interactions develop 
between the compound and its potential partners (Figure 18). After 
centrifugation, the solid phase was submitted to several washing steps useful 
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to reduce non-specific interactions, while the tightly bound proteins were then 
eluted and resolved by 12% SDS-PAGE (Figure 18).  
 
 
Figure 18. Experimental workflow used to profile SUV interactome. 
 
Both gel lanes were cut into ten pieces and subjected to in situ digestion[146]. 
The peptide mixtures were then analysed by nano-flow RP-HPLC MS/MS, 
and protein identification was achieved by submitting the peak lists to Mascot 
database  search. The list of  identified proteins was refined by removing the 
hits found in the control experiments. The results of five independent 
experiments were combined to generate a smaller list of putative SUV 
interactors. On the basis of the highest peptide matches (Table 2), Heat shock 
protein 60 (HSP60)  was recognized as the prominent SUV biological target.  
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Table 2. List of SUV partners identified in five independent chemical proteomics 
experiments. The results are reported in terms of number of identified peptides. 
 
Heat shock proteins are molecular chaperones that guide several steps during 
synthesis, transportation, and degradation of proteins[147], and are highly 
conserved and abundant in the cell[148]. During stress, their synthesis is rapidly 
up-regulated (in prokaryotic as well as in eukaryotic cells), and changes in 
intracellular location have been observed, including their expression on the 
cell surface[149]. Mammalian HSP60 is also an important auto-antigen during 
chronic inflammation or atherosclerosis[150] and exhibits immunoregulatory 
properties, primarily by inducing pro-inflammatory responses in innate 
immune cells[149]. Moreover, HSP60 was found to synergize with IFN-γ in its 
pro-inflammatory activity modulating gene expression of the cytokines IL-12 
and IL-15[150]. Thus, we moved  toward the validation of the direct interaction 
between HSP60 and SUV, and to assess the potential alteration of the 
chaperone activity. 
 
 
2.3 In vitro validation of HSP60-suvanine interaction 
  
The ability of SUV and SUV-AL to interact with HSP60 was further explored 
by exposing samples of the control and suvanine-bearing beads to recombinant 
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(human) HSP60[151]. The experimental workflow was very similar to that 
described above during the fishing of the SUV interactors from the cell 
extracts. Thus, after 1h of incubation and abundant washings, both CTR-
matrix and SUV-matrix were exposed to a high denaturing buffer, and then the 
eluates were subjected to SDS-PAGE. Comparative analysis of the obtained 
gel (Figure 19A) showed a significant enrichment of HSP60 in the experiment 
with SUV, compared with the control, thus confirming a direct binding 
between the small molecule and the protein target. 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. A) SDS-PAGE of HSP60 (~60kDa) on suvanine-modified beads (SUV) and 
control beads. B) HSP60 binding to suvanine-modified beads is reduced after incubation of 
HSP60 with SUV and SUV-AL at different  concentrations. C) Western blots on eluates from 
suvanine-modified and control beads (CTR) after incubation with HeLa cell lysate, by using 
HSP60, HSP70, and HSP90 antibodies. 
 
Then, we tested the binding of both SUV and SUV-AL in their free forms to 
HSP60, by pre-incubating  human  recombinant protein with each molecule at 
different concentrations, and then treating these mixtures with samples of 
SUV-bearing beads. The resulting gel (Figure 19B) showed that both 
molecules formed stable complexes with HSP60, hampering its capture by the 
modified beads. The binding specificity of SUV and SUV-AL with HSP60 
Results and Discussion 
 
- 50 - 
 
was also assessed against a group of heat shock proteins, such as HSP70 and 
HSP90. In some details, after exposing the SUV-modified beads to a sample 
of HeLa cells extract, the eluted proteins were analysed trough western 
blotting using antibodies directed anti-HSP60, HSP70 and HSP90. The blots 
reported in Figure 19C clearly showed a selective enrichment of HSP60 by 
SUV, while HSP70 and HSP90 were also detected in the control experiment.  
Because of the relevance of HSP60 into inflammation and immune responses, 
our investigation were deepened by using surface plasmon resonance (SPR) 
for the measurement of the protein affinity to both SUV and SUV-AL. HSP60 
was immobilized on a CM-5 sensor chip and both molecules were separately 
injected at various concentrations onto the chip (0.5–10 µΜ). The resulting 
sensogram curves (Figure 20) were analysed by curve fitting (1:1 Langmuir 
algorithm), giving dissociation constants (KD) of 0.6 (±0.5) and 1.0 (±0.8) µM 
for SUV and SUV-AL, respectively, that suggested the occurring of strong 
interactions between the counterparts. 
 
 
Figure 20. Sensogram curves for the binding of SUV (A) and SUV-AL (B) (0.5–10 µM) with 
HSP60. Each experiment was performed at least in triplicate. 
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2.4 HSP60 chaperone activity inhibition by Suvanine  
 
Then, we wanted to assess if the affinity of SUV and SUV-AL with HSP60 
could also affect its chaperone activity. Thus, the ability of HSP60 to refold 
the citrate synthase (CS) to its active state under non-permissive conditions (to 
minimize spontaneous refolding) was tested in vitro in presence and absence 
of our compounds[152, 153]. This is a convenient assay, since both thermally and 
chemically induced CS unfolding and refolding can be easily monitored by a 
colorimetric test[152]. Indeed, as schematically reported in Figure 21 and 
explained in the experimental section, the completely folded CS is able to 
catalyse the production of citrate and CoA from Oxalacetate and Acetyl-CoA. 
Thus, the activity of CS can be spectrophotometrically monitored at 412 nm 
by adding 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) that, reacting with 
CoA, produces the 2-nitro-5-thiobenzoate anion (TNB), an intense yellow 
coloured compound. 
In our experimental design, CS was chemically unfolded by guanidine and 
then refolded after addition of the HSP60–HSP10 complex. 
 
 
Figure 21. Schematic representation of the colorimetric assay employed to evaluate SUV and 
SUV-AL capability to inhibit HSP60 activity 
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 As shown in Figure 22, CS recovers about 80% of its activity after its 
refolding induced by HSP60–HSP10, whereas in the presence of different 
amounts of SUV and SUV-AL, the enzyme recovery was decreased as a result 
of the inhibition of the HSP60–HSP10 chaperone activity. 
  
Figure 22. Inhibitory effects of SUV (light gray) and SUV-AL (dark gray) on HSP60 
refolding of CS. The data are shown as percentage of CS activity relative to native CS. 
Activity of CS refolded in the presence of HSP60 pre-incubated with I: 3.2 µM SUV, 32 µM 
SUV-AL; II: 16 µM SUV, 80 µM SUV-AL; III: 32 µM SUV, 160 µM SUV-AL. 
 
To exclude a direct activity of SUV and SUV-AL on CS, we replicated the 
same experiment in permissive condition. At room temperature, CS recovered 
its activity in absence of molecular chaperones, even in presence of both 
molecules. 
It is noteworthy that SUV showed a greater inhibitory effect  than its aldehyde 
congener on the HSP60–HSP10 chaperone activity despite their similar 
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dissociation constants. This could be attributable to the charged sulphate 
functionality on SUV, which could enhance HSP60 inhibition. A similar 
behaviour was also reported in the case of the PLA2 inhibition[141]. 
All the collected data demonstrate that SUV is able to interact with HSP60 
inhibiting its chaperone activity. The identification of SUV as a new HSP60 
inhibitor could be helpful for future studies on the human HSP60 mechanism 
of action. Moreover, since this inhibition is strictly connected with the anti-
inflammatory properties of SUV, this finding opens the way to the rational 
design of new potential anti-inflammatory drugs. In fact, despite the 
importance of this protein in immunoregulatory and inflammatory processes, 
only few examples of natural compounds, such as mizoribine[154] and 
epolactaene[155], have been reported as HSP60 inhibitors.  
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-CHAPTER 3- 
 
 
Heteronemin, a marine sponge terpenoid, targets TDP-43, a 
key factor in several neurodegenerative disorders. 
 
 
 
 
 
Based on: Chem. Commun. (Camb.), 2013, 50, 406–408 
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3.1 Affinity purification and identification of HET partners 
 
The identification of the entire cellular interactome of a bioactive natural 
product is crucial to define its specific mechanism of action, giving a rational 
support to the observed pharmacological effect[156] and also to identify its off-
target activities responsible for multi-pharmacological and/or side effects. 
Natural compounds are recognized as unique and essential biological probes, 
mainly due to their peculiar, high functionalized structures. Often, these 
characteristics are responsible for a multi-target behaviour that should be 
accurately defined to have a deep comprehension of their pharmacological and 
toxicological properties.  
Heteronemin (HET) (Figure 23) is a marine sesterterpene endowed with a 
significant pharmacological profile, isolated from the sponge Hyrtios sp.[157]. 
Indeed, HET has been recently discovered as a potent modulator of the TNFα-
induced NF-κB pathway, driven by the inhibition of the proteasome system, 
and also recognized as an apoptosis inducer[158]. Due to these interesting 
properties, HET has been considered a good candidate for the application of a 
chemical proteomic approach.  
 
 
 
Figure 23. HET structure 
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The natural compound was first immobilized onto an epoxy activated 
sepharose beads by means of the alcoholic function located on the C ring 
(Figure 24). To assess the reaction yield, integration of RP-HPLC-UV peak 
areas of  the free HET before and after 2.5 h of reaction in ACN/NaHCO3 was 
performed (Figure 24). Once recovered around 75% of reaction yield, 
corresponding to 16 µmol of HET per ml of resin, the coupling  process was 
completed by the inactivation of the free epoxy-groups of the resin with 
isopropanol.  
 
Figure 24.  Reaction scheme of HET immobilization on sepharose beads and HPLC profile of 
free HET before and after coupling reaction. 
 
Then, crude extracts from HeLa cells were incubated with a sample of the 
HET-bearing matrix to promote the interactions between the compound and its 
potential protein partners. After removal of the soluble phase, several washing 
steps were done on the solid phase to reduce non-specific adsorption, while the 
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tightly bound proteins were eluted with a strong denaturing buffer and then 
resolved by 12% SDS-PAGE (Figure 25). In order to distinguish between 
specific and residual non-specific interactions, a control experiment was 
performed with a sample of epoxy-sepharose beads inactivated with 
isopropanol. On the basis of the comparison between the control and sample 
gel runs, three bands, at 60, 45 and 20 kDa, were clearly enriched in the HET-
related gel lane. 
 
 
 
Figure 25. SDS-PAGE of the eluted proteins from HET and control-beads; the arrow 
corresponds to the band of TDP-43. 
 
After triplication of the experiment on fresh cell lysates, the three bands were 
cut from each independent experiment, together with the corresponding bands 
of the control experiment, and subjected to in situ digestion[146]. The peptide 
mixtures were then analysed by nano-flow RP-LCMS/MS, and protein 
identification was achieved by submitting the peak lists to Mascot database 
search. Superimposition of all the results gave the identification of tubulin in 
the band at 60 kDa, which was also present, even if in lesser amount, in the 
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control lane, TAR-DNA-binding protein 43 (TDP-43) and proteasome 
subunits α in the bands at 43 and 20 kDa, respectively, which were fully 
absent in the correspondent control bands. On the basis of these data, the 
proteasome complex and TDP-43 were recognized as main partners of HET, 
the first one already reported in literature[158], while TDP-43 as new potential 
interactor. 
The binding affinity of HET with TDP-43 was then assessed by immuno-
blotting and surface plasmon resonance (SPR) analyses.  
HET-modified beads and control beads were exposed to HeLa cell extracts 
and eluted proteins were analyzed by western blotting using an anti-TDP43 
antibody. In the eluates coming from the HET-bearing matrix, a relevant 
enrichment of TDP43 was clearly visible (Figure 26) 
 
 
 
Figure 26. Western blot analysis on proteins eluted from control and HET-beads incubated 
with HeLa cell lysates.   
 
The interaction affinity between the marine compound and TDP-43 was 
measured through SPR experiments. The protein was immobilized onto the 
chip and HET was injected at various concentrations (from 0.01 to 25 µM). 
The resulting sensorgrams (Figure 27) were analysed by curve fitting (1:1 
Langmuir algorithm) giving a dissociation constant (KD) of 270±120 nM for 
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the TDP-43-HET complex, thus suggesting a relevant interaction between the 
counterparts. 
 
 
 
Figure 27. Sensorgrams obtained from  the binding of HET (0.01–25 µM) to immobilized 
TDP-43. 
 
TDP-43 is an abundant and ubiquitous protein, well-conserved among 
mammals and invertebrates[159]. Firstly identified as a binding partner of the 
human immunodeficiency virus TAR DNA element[160], TDP-43 is known to 
be involved in transcriptional repression, exon splicing, mRNA generation, 
cell cycle regulation and apoptosis[161]. By means of two recognition motifs 
(RRMs), termed RRM1 and RRM2, TDP-43 binds both mRNA and DNA, 
thereby regulating mRNA splicing, stability and translation as well as gene 
transcription[162].  
TDP-43 is also one of the major components of tau-negative and ubiquitin-
positive inclusions that characterize amyotrophic lateral sclerosis (ALS) and 
front-temporal lobar degeneration (FTLD) linked to TDP-43 pathologies 
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(FTLD-TDP)[163]. The disease-related TDP-43 protein is characterized by 
hyper-phosphorylation, cleavage, ubiquitination, mislocalization and 
aggregation into insoluble aggregates[164-166]. Moreover, although TDP-43 
regulates mRNA levels under normal physiological conditions, some evidence 
indicates that TDP-43 is a stress-responsive RNA-associated factor. Exposure 
to a variety of stressors, which promote oxidative stress, and to heat shock 
leads to accumulation of insoluble TDP-43 aggregates similar to those 
observed under pathological conditions[167,168]. More recently, several studies 
have demonstrated that exposure to stress causes TDP-43 re-localization into 
stress granules (SGs), cytoplasmic foci that represent both sites of translational 
stalled RNAs and active sites of RNA regulation and sorting[169,170]. Although 
the descriptive nature of SG localization reveals a physical incorporation of 
TDP-43 within SGs, whether TDP-43 has an active role or a causal role within 
SGs remains uncertain. 
On the basis of the relevance of TDP-43 in several neurodegenerative 
disorders, our study has been extended to the evaluation of the HET effects on 
TDP-43 biological activity, whose results will be discussed below. 
 
 
3.2 HET enhanced TDP-43 aggregation in vitro  
 
In several neurodegenerative disorders, TDP-43 becomes increasingly 
insoluble showing an aberrant pattern of phosphorylation and 
ubiquitination[171]. Therefore, we focused our attention on the modulation of 
the TDP-43 aggregation state induced by HET through immunoblot analysis. 
TDP43 has a strong tendency to form high molecular weight aggregates both 
in vitro and in cell[171]. Indeed, the recombinant TDP43 easily aggregates upon 
gentle mixing at room temperature[172]. Therefore, as suggested by Cohen and 
co-workers[172], TDP-43 was stored at high concentrations in a detergent-
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containing buffer (25 µM in 33% glycerol, 80 mM Tris-HCl, 0.1% SDS 1 mM 
DTT) in order to keep TDP-43 in a non-aggregated state, and then 
immediately diluted (1:500) and added to HET (50 folds molar excess) or 
DMSO as control. Samples were then centrifuged and both pellets and 
supernatants were carefully separated and diluted with a mix of urea and 
thiourea before loading on a 10% SDS-PAGE. As shown in Figure 28, the 
treatment of TDP-43 with HET resulted in an increased amount of high 
molecular weight bands corresponding to TDP-43 supra-molecular adducts 
insoluble in urea buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Western blotting analysis of the pellet and supernatant fractions of recombinant 
TDP43 treated or not with HET 2.5 µM. 
 
 
3.3 HET inhibits bt-TAR-32 DNA binding to TDP-43 
 
Several reports have indicated that the solubility of TDP-43 is largely 
influenced by its binding to the cognate single-strand DNA (ssDNA) or RNA 
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(ssRNA), suggesting an intimate relationship between TDP-43 aggregation 
process and the factors that alter its DNA or RNA binding affinity[173]. Since 
the single strand (ss)-DNA bt-TAR-32 is well known to specifically targets 
TDP-43[174], we moved to measure the HET effect on this binding by 
Amplified Luminescent Proximity Homogeneous Assay Screen (alpha-screen) 
[175]
. The application of this versatile technology, a bead-based proximity 
assay, allowed us to measure the potential inhibiton of the oligonucleotide 
binding to TDP-43 by HET. Briefly, samples of GST-fused TDP-43 and 
biotinylated ssDNA were bound on photosensitive acceptor and donor beads, 
respectively, and their affinity was measured by recording the intensity of the 
chemiluminescent signal produced during the interaction event, in presence 
and absence of HET (Figure 29).  
Figure 29.  Schematic representation of Alpha screen experiment. 
 
As reported in Figure 30, HET produces a concentration dependent reduction 
of the signal relative to TDP-43 interaction with ssDNA, with a measured IC50 
of 10.1±0.5 nM. This evidence connects the mere interaction between TDP-43 
and HET to a specific biological effect of the marine metabolite on the protein 
function, that is a relevant inhibition of the TDP-43 binding to its DNA target 
strand. Since the TDP-43 RNA-recognition domains RRM1 and RRM2, 
strictly involved in the DNA or RNA binding, are located in the middle 
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domain of the protein, on the basis of our results a possible interaction of HET 
with this region can be postulated. 
 
 
 
Figure 30. Inhibition of bt-TAR-32 binding to TDP-43 by HET by alpha-screen. Data are 
reported as percentage of bt-TAR-32 bound vs log [Het]. The curve was convoluted using 
GraphPad Prism. Each point represents three determinations from three experiments. 
 
 
3.4 HET increases cytoplasmic TDP43 content and its localization in 
stress granules. 
 
To deeply investigate the effect of HET on TDP-43 in the whole cell 
compartment, HeLa cells were incubated with the marine metabolite and/or 
heat-stressed, and then analyzed by immunofluorescence. These experiments 
were planned to measure the potential involvement of HET in the TDP-43 
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cellular localization in HeLa models. Additionally, since the heat stress 
treatment has been reported to drive TDP-43 into stress granules[176,177], we 
were also interested in measuring the effect of our marine drug on this 
pathway. An immunofluorescence assay was used to observe the TDP-43 
cellular localization. HeLa cells were incubated with HET at 10 µM for 2h and 
then with different primary antibodies, one against TDP-43 and another 
against a stress granules marker called HuR (human antigen R). The labelling 
was visualized with fluorescently conjugated secondary antibodies.  
As expected, in the vehicle (less than 1% DMSO) treated cell sample the TDP-
43 expression is restricted to the nucleus and no stress granules were present in 
the cytosol (Figure 31a). After a heat-shock treatment of 1h at 43°C, many 
SGs were formed in the cell cytosol, together with a low quantity of TDP-43 
coming from the nucleus (Figure 31b). Upon treatment with HET 10 µM for 
2h, a clear cytoplasmic accumulation of TDP-43 was observed with no 
evidence of stress granules development (Figure 31c). When HeLa cells were 
first incubated with HET for 2h and then heat shocked for 1h a clear increase 
of HuR positive and TDP-43 positive SGs were observed (Figure 31d). In 
order to quantify the differences between the sample treated or not with HET 
and heat-shocked at 43°C, we compared the counts of HuR positive granules 
(SGs) and the TDP-43 positive SGs. While in the HET treated cell sample 
very few SGs were detected, a relevant number of HuR-positive SGs was 
found in the heat-shocked cells. Moreover, when the cells were pre-treated 
with HET before heat shock, the increase of the total SGs and of TDP43 
positive SGs per cell was higher than the control untreated cells (Figure 32), 
thus indicating that HET promotes TDP-43 aggregation also in a living cell 
system. All experiments were repeated in presence of MG132, a known 
proteasome inhibitor, which induced the formation of SGs and TDP-43 
positive SGs only in a very low extent in respect to HET (Figure 32).    
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Figure 31 HeLa cells cultured on cover slips were left untreated (a) or pre-treated with 10 µM 
HET (c), then 43 °C heat shocked (b,d) and  subsequently immuno-labeled for TDP-43 and the 
SG marker HuR. TDP-43 localization to SGs is indicated by the merged images showing the 
overlap between red and green signals 
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Figure 32. TDP-43 and HuR-positive SGs were counted in HS, HET+HS and MG132 treated 
cells. A minimum of 200 cells were counted across multiple fields of view (and multiple 
coverslips) for each treatment. The total number of HuR or TDP-43 positive SGs was divided 
by the total number of cells to provide a mean measure of SGs per cell. Data were expressed 
as fold induction of HuR positive mean SGs in HS cells set to 1. 
 
Since it is reported that HET inhibits TNFα-induced NF-κB activation through 
proteasome inhibition in chronic myelogenous leukemia cells[158] and a clear 
involvement of the proteasome inhibition in the cytoplasmic accumulation of 
TDP-43 in some neuronal cells is also reported[178], we performed a following 
experiment to exclude the possibility of a proteasome inhibition by HET in 
HeLa cells. In details, proteasome activity was measured upon HET 
administration to HeLa cells by detecting the proteasome-mediated proteolysis 
of a fluorogenic peptide substrate, specific for the chimotrypsin catalytic 
subunit[114]. Since the chimotrypsin-like activity of the HeLa proteasome was 
not impaired  by the treatment with HET for 2 h at 10 µM (Figure 33), the 
previously measured biological effect of HET on TDP-43 cellular localization 
can be evidently attributed to the direct interaction between the counterparts. 
MG 132, a known proteasome inhibitor, was used as positive control. 
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Figure 33. Analysis of proteasomal chimotrypsin-like activity. Inhibition in HeLa cells by 
HET and MG132. 
 
Finally, to confirm the immunofluorescence data by independent experiments, 
immunoblot analysis was carried out separately on the supernatants and pellets 
portions upon HET and vehicle treatment of HeLa cell lysates. As clearly 
reported in Figure 34, HET confirmed its ability to induce an accumulation of 
insoluble TDP-43 species found in pellets whereas MG132, used as control, 
did not affect the TDP-43 solubility profile. 
 
 
 
 
 
 
 
 
 
Figure 34. Western blotting analysis of TDP43 found in supernatant (soluble proteins, a) and 
pellet (b) fractions of HeLa cell lysates treated or not with HET 10 µM and MG132 50 µM. 
Histograms were the results of image quantification analysis of three independent 
experiments. 
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Huang and coworkers[173] recently reported that TDP43 aggregation is mostly 
retarded or even prohibited in the presence of its cognate DNA/RNA, and that 
the loss of the binding ability to DNA/RNA causes TDP-43 to form large 
aggregates. Thus, since our TDP43/bt-TAR-32 binding analysis revealed the 
role of HET in lowering the TDP43 affinity to its target DNA, and the 
following experiments demonstrated the HET-induced cytoplasmic 
translocation and aggregation of TDP43, a mechanistic insight could be 
depicted, in which the marine compound targets TDP-43 lowering its affinity 
towards nucleic acids, that in turn induces a translocation of the protein to the 
cytoplasm and a consequent tendency to form insoluble aggregates in the form 
of stress granules. This stress granules are known to contribute to the 
pathogenesis of several disorders, including fragile-X syndrome, spinal 
muscular atrophy, and ischemia reperfusion injury, caused by altered RNA-
binding proteins [164-167].  
Our findings provide the evidence that HET is involved in the binding, 
solubility alteration, subcellular localization and formation of small nuclear 
inclusions of TDP-43 protein. These data suggest a role for this marine 
compound as a novel stressor and promoter of TDP-43 localization to HuR 
positive stress granules, and consequently as a relevant chemical tool in TDP-
43-based cellular investigations.   
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In cell chemical proteomics by copper-catalyzed Huisgen 1,3 dipolar 
cycloaddition 
 
 
 
 
 
 
 
 
 
 
Based on: “In cell Scalaradial Interactome Profiling Using a Bio-Orthogonal 
Clickable Probe” Submitted 
Results and Discussion 
 
 
 
- 72 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 
 
- 73 - 
 
4.1 Background 
 
Mass-spectrometry-based chemical proteomics has been revealed as a 
powerful technique to define the interactome of bioactive compounds opening 
the way to the design of new therapeutic or biotechnological tools[114,115]. As 
extensively discussed in the introduction (see chapter 1), classical 
methodologies based on the in vitro employment of small-molecules anchored 
on solid supports, are characterized by some limitations, mostly due to cellular 
lysis. In fact, this process exploits sonication or detergents that can alter the 
multi-protein complexes or even lead to a change in the protein conformation, 
in turn compromising the interaction with the small molecule probe[180]. 
Moreover, in vitro protocols require the immobilization of the small molecule 
onto a solid surface, which could orient the molecule into a forced 
conformation altering the recognition of some potential interactors[9]. For these 
reasons, new approaches based on the bio-orthogonal chemistry have been 
proposed to recover the targeted proteins of a small molecule in living 
systems. As a matter of fact, bio-orthogonal reactions have demonstrated to be 
highly reliable, selective and bio-compatible, finding a large employment in 
ABPP procedures and applications in the fields of bio-organic chemistry, drug 
discovery, proteomics and DNA research[181]. Substantially, three organic 
reactions, belonging to the class of the so-called click-chemistry approaches, 
have proven to match the bio-orthogonality criteria, that are kinetics, 
selectivity and compatibility with non-organic solvents: the copper-catalysed 
azide-alkyne cycloaddition, the Staudinger-Bertozzi ligation, and the copper 
free cycloaddition (see chapter 1). The former one, a variant of the  Huisgen’s 
1,3-dipolar cycloaddition, is to date the most investigated click-chemistry 
reaction, and relies on the ability of an azide and a terminal alkyne to yield a 
stable triazole ring in presence of Cu(I) as a catalyst[182,183].  
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Aiming the optimization and tuning of an in cell protocol to “fish out” the 
macromolecular partner(s) of a small molecule, we first applied the in vitro 
pull down method to identify the targets of Scalaradial (SLD), and then we 
used these results as a reference point for the development of the new in cell 
approach.  
SLD is a sesterterpenoidic molecule with a scalarane-skeleton, isolated by 
Cimino and co-workers[184,185] from the sponge Cacospongia mollior, endowed 
with a relevant anti-inflammatory profile both in in vitro and in vivo models 
[186-190]
. 
The experimental workflow for the in vitro approach is almost similar to that 
previously described for Suvanine (chapter 2) and Heteronemin (chapter 3)  
(Figure 35A), save that we employed a spacer arm containing a cleavable site. 
This kind of linkers are useful to perform the targets elution step in non-
denaturing conditions, allowing also the minimization of the background 
proteins (Figure 37). Briefly, SLD was (i) functionalized with a di-amine 
linker containing a disulphide bond and immobilized onto a solid support; (ii) 
then,  the SLD-bearing matrix was used in the affinity chromatographic step, 
and  (iii) after several washings, the tightly bound proteins were recovered by 
breaking the disulphide bond with a reducing agent and then identified with 
nanoLC-MSMS. In the last step (iv) western blot analysis and surface plasmon 
resonance were employed to validate the obtained results. 
The in cell protocol starts with the decoration of the small molecule with an 
appropriate functional group for the bio-orthogonal reaction, such as an azide 
or a terminal alkyne. Then, the living cell sample is treated with the tagged 
molecule to allow its translocation inside the cells and develop the interactions 
in a native environment. After a mild lysis the cell content is treated with the 
appropriate mixture of reagents to promote the linking of the drug, carrying its 
selected protein partners, onto a solid matrix (Figure 35B). On this basis, we 
chemically modified SLD with an azide-bearing spacer arm and then 
Results and Discussion 
 
- 75 - 
 
optimized the conditions of the copper catalyzed Huisgen cycloaddition 
reaction in solution, before the application in a living cell context. 
In vitro
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Live cells
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Figure 35. Workflow of in vitro (A) and cell-based (B) chemical proteomics of small 
molecules followed by nano-ESI-LCMSMS targets identifications. 
 
 
4.2 In vitro SLD Proteome Profiling 
 
The in vitro affinity purification experiments was carried out immobilizing 
SLD on carbonyl-di-imidazole (CDI) agarose beads through the insertion of  
an opportune spacer arm, between the matrix and the molecule, to minimize 
steric hindrance during the affinity chromatography phase.  
The immobilization was achieved in two steps: (i) SLD was first linked to the 
2-(2-amino-ethyl-disulfanyl)-ethyl-amine linker (TIOS), exploiting the 
reactivity of the SLD di-aldehyde moiety with the terminal amino group of the 
spacer arm (Figure 36), and (ii) then the obtained adduct was linked to the 
CDI solid support. The reaction between SLD and TIOS was monitored by 
RP-HPLC-MSMS and produced, in 1h, a covalent SLD-TIOS adduct (Figure 
36A). The reaction mechanism was postulated on the basis of our previously 
published data[189,190] and of MS and MSMS analysis. In particular, a Schiff 
base intermediate, formed after reaction between the TIOS amino group and 
one of the aldehyde moieties on the SLD D ring, evolved in a pyrrole adduct 
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by elimination of a water molecule. This last product was then purified by 
mean of RP-HPLC-UV and put in reaction with the CDI-agarose matrix. The 
immobilization, mediated by a condensation reaction between the primary 
amine of SLD-TIOS and the carboxyl group onto the matrix surface, was 
monitored by RP-HPLC-UV after injection of  small aliquots of the reaction 
suspension and integration of  the SLD-TIOS peak areas at t=0 and after 16 h 
of reaction (Figure 36B). 
.
  
 
Figure 36. A) SLD-TIOS formation reaction scheme and MS and MS/MS spectra. MS 
spectrum, shows the MH+ of SLD-TIOS at m/z of 545.3 and its spontaneous fragment at m/z 
of 485.3, produced by in-source loss of acetic acid. The MSMS spectrum shows also a peak at 
m/z of 408.3 corresponding to the induced loss of 2-aminoethanethiol. B) SLD-TIOS 
immobilization on CDI agarose solid matrix. HPLC-UV trace at 220 nm of reaction 
supernatant after 0, 4, 16 h of reaction. 
 
Then, the SLD-bearing matrix was used as a bait in the affinity 
chromatography experiments with crude HeLa cells extracts. After keeping the 
suspension under rotary shaking for 1h at 4°C, the  unbound proteins were 
discarded and the low affinity bound proteins removed after several washings 
with a saline buffer. The tightly bound proteins were recovered after cleavage 
of the disulphide bond of the linker with DTT, a typical expedient allowing the 
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reduction of the unspecific proteins content (Figure 37). Furthermore, to 
definitively exclude background proteins, a control experiment was performed 
incubating a matrix-linker adduct sample with the same cellular lysate.  
Proteins eluted from both resins (SLD and CTR matrixes) were then resolved 
by 12% SDS-PAGE (Figure 37). 
 
Figure 37. Representation of the experimental workflow for in vitro SLD pull down. Proteins 
selected by SLD and control matrix were released by cleaving the disulphide bridge contained 
in the spacer arm and separated by SDS-PAGE. Visible enriched bands were in situ digested 
and analysed through LC-MSMS. 
 
The gel lane portions framed  within the black boxes (Figure 37) were divided 
in a few pieces and subjected to an in situ digestion protocol. The peptide 
mixtures were finally analysed through nano-flow RP-HPLC-MSMS and the 
proteins identified by submitting the peak lists to the Mascot database. 
The list of the SLD interacting proteins was refined by removing the hits 
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shared with the control experiments and superimposing the results of  three 
independent experiments. This refinement led to the identification of several 
members of the 14-3-3 and peroxiredoxin families (Figure 38).  
 
 
 
 Figure 38. List of SLD interacting proteins obtained after removing hits shared with control 
and superimposing results from experiments. Number of peptides matched in best MASCOT 
identification  is reported 
 
Due to the high identification scores, we chose 14-3-3ε and PRX1, whose 
interaction was validated by western blotting and surface plasmon resonance, 
as reference probes for the optimization of the in cell protocol. Briefly, the 
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proteins eluted from the control and SLD resin beads were blotted using 
antibodies anti-14-3-3ε and anti-PRX1. The enrichment of the two proteins in 
the SLD lanes compared to the control was evident (Figure 39), confirming 
the mass-spectrometric results. 
 
 
Figure 39. Western blot analysis using 14-3-3ε and PRX1 as probes on proteins eluted in two 
independent experiments from control and SLD-beads after incubation with HeLa cell lysates. 
 
The interactions of SLD with 14-3-3ε and PRX1 were further confirmed by 
SPR, allowing also the calculation of the respective dissociation constants. 
The SPR assay was performed by immobilizing both proteins onto a CM5 
sensor chip and injecting solutions containing increasing amounts of SLD. The 
resulting dissociation constants of 2.24±2.07 and 0.99±0.18 µM for PRX1 and 
14-3-3ε, respectively, suggested a relevant interaction between the 
counterparts (Figure 40).  
 
 
Figure 40. Sensorgrams obtained from the binding of SLD (0.01–25 µM) to immobilized 
PRX1 (A) and 14-3-3 ε (B). 
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4.3 In cell Scalaradial proteome profiling 
 
4.3.1 Design and synthesis of SLD-AZ:  
The in cell fishing for partners experiment started with the functionalization of 
SLD with an azide containing linker (Figure 35B). Even if, from a theoretical 
point of view, both functional groups (alkyne/azide) are feasible, our choice 
was due to the reported potential reactivity of alkynes in the cellular 
environment[191]. In particular, the 11-azido-3,6,9-trioxaundecan-1-amine 
(TRX-AZ, Figure 41) linker was chosen for its stability and solubility in 
aqueous buffer, and for its permeability toward the cellular membranes[192]. 
The reaction was carried out under stirring for 1h at 25°C in ACN 0.5% 
triethylamine using a 10-fold molar excess of the TRX-AZ linker. The product 
formation was monitored by RP-HPLC-UV, MS and MSMS analyses (Figure 
41).  
 
 
Figure 41. Panel A reports SLD-TRX-AZ interaction pathway. Panel B shows its HPLC-UV 
trace, MS and MS/MS spectra. In the MS spectrum, the base peak at m/z of 611.8 corresponds 
to MH+ of SLD-AZ adduct whereas its fragment at m/z of 551.7, visible in MSMS spectrum, 
is due to the loss of acetic acid. 
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A species at 610.8 Da was monitored and recognized as the final product, 
confirming the same reaction mechanism proposed for SLD-TIOS. The 
reaction was finally scaled-up and the SLD-AZ probe purified by RP-HPLC 
and lyophilized. 
 
4.3.2 Click Chemistry Optimization 
 
Since a variety of conditions for a Cu(I) catalysed azide-alkyne cyclization are 
reported, we performed the reaction in different experimental settings to find 
out the best conditions for our experiment. 
Indeed, the cycloaddition catalytic cycle relies on Cu(I) (Figure 42), a very 
unstable species. 
 
 
Figure 42. Copper catalyzed cycle of azide-alkyne cycloaddition 
 
The improvement of the reaction yield is obtained employing Cu(II)SO4 in 
presence of a reducing agent, able to generate Cu(I) in situ, together with a 
stabilizing agent. We chose Na-Ascorbate as reducing agent and Tris-[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) as stabilizer. The reaction 
conditions were optimized exploring the reactivity of SLD-AZ with the 
selected acetylene counterpart, 4-pentyn-1-amine (PINA linker, Figure 43A), 
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working in a bio-mimetic context, even if in absence of the proteins. 
Therefore, SLD-AZ was treated with PINA in a saline buffer (PBS at pH 7.4) 
containing a small amount of DMSO (less than 10 %), to increase the reagents 
solubility. The reaction was monitored by RP-HPLC-UV and MS analyses. 
The best result, in terms of reaction yield and kinetics, was obtained using 100 
µM CuSO4, 5 mM Na-Ascorbate and 100 µM TBTA under nitrogen, as 
proven by the monitoring, after 30 minutes of reaction, of a triazole adduct at a 
retention time of 23 min (m/z 694.45 Th, ,Figure 43 B).  
 
 
 
Figure 43. Panel A reports SLD-AZ interaction pathway with the linker PINA. Panel B shows 
HPLC-UV trace, MS and MS/MS spectra of the product. In the MS spectrum, the base peak is 
at m/z of 694.5 corresponding to MH+ of SLD-AZ adduct with PINA linker, its fragments at 
m/z of 677.3 and 634.5, visible in MSMS spectrum, are the loss of ammonia and acetic acid, 
respectively. 
 
Once established the ability of SLD-AZ and PINA to give rise to the expected 
product in solution, we moved to analyse their reactivity in a cell lysate by an 
in situ click chemistry-based pull down assay (Figure 44).  Therefore, SLD-
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AZ adduct (1 and 10 nmol) was incubated with HeLa cell lysates for 1 h at 
4°C, and then mixed with 50 µL of CDI-Agarose matrix bearing PINA linker, 
in presence of 100 µM CuSO4, 5 mM Na-Ascorbate and 100 µM TBTA under 
nitrogen. As control, the experiment was carried out in the same conditions 
using TRX-AZ as a probe. The solid phase was extensively washed in PBS 
buffer and SLD partners were eluted, separated by 12% SDS-PAGE and 
revealed through immunoblotting using anti-14-3-3ε and anti-PRX1 antibodies 
(Figure 44).  
 
 
 
Figure 44. Schematic workflow of an in situ click chemistry-based pull down assay used to 
optimize Huisgen cycloaddition in presence of protein extract. 
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As reported in Figure 45, 10 nmol of  SLD-AZ selectively fished out 14-3-3ε 
and PRX1, as demonstrated by the presence of  a slight band only in the SLD-
AZ lane. To improve the reaction yield, the experiment was replicated using 
10 nmol of SLD-AZ and modifying the click-chemistry reaction conditions 
(250 µM CuSO4, 2.5 mM Na-Ascorbate and 500 µM TBTA, under nitrogen). 
As reported in Figure 45B, the new experimental conditions prompted a 
further enrichment of the selected proteins.  
 
Figure 45. Western blot analysis on proteins eluted from control and SLD-beads incubated 
with HeLa cell lysates (in vitro) using 14-3-3ε and PRX1 as probes. Panel A and B are relative 
to SLD-based pull down using different quantity of metabolite and different click chemistry 
conditions  as reported. 
 
   
 4.3.3 Large-Scale Pull-Down/LC-MS/MS analysis  
 
The in cell pull down experiments were preceded by the measure of the effects 
of SLD-AZ on HeLa cell proliferation, applying the MTT assay and 
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comparing the results with that of SLD. As shown in Figure 46, both 
molecules showed the same profile, and did not affect the cell viability at the 
tested doses.  
 
 
Figure 46. MTT analysis shows that both SLD and SLD-AZ does not affect HeLa cell 
proliferation at tested doses. 
 
HeLa cells were then treated with 1 µM SLD-AZ and 1 µM TRX-AZ, as 
control for 6 hours, to allow the drug internalization and the cellular target(s) 
selection. Cells were then washed with PBS to remove the un-internalized 
drug residue, and lysed by mean of dounce homogenization with a gentle lysis 
buffer. Both lysates were then separately treated with 250 µM CuSO4, 2.5 mM 
Na-Ascorbate, 500 µM TBTA and 10 µL of PINA-bearing matrix under 
nitrogen for 45 minutes at room temperature, to promote the modified Huisgen 
1,3-cycloaddition. Moreover, a parallel reaction without Na-Ascorbate was 
carried out to provide an additional negative control. Proteins fished out from 
the three resin samples were then separated by SDS-PAGE and subjected 
either to immunoblotting or coomassie staining.   
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As reported in Figure 47, immunoblotting showed that both PRX-1 and 14-3-
3ε were clearly enriched by SLD-AZ, confirming the effectiveness of the in 
cell approach in the finding of a small molecule interactors. 
 
 
Figure 47. 14-3-3ε and PRX 1 enrichment operated by SLD-AZ in live HeLa cells fished out 
by CDI-Agarose beads modified with PINA linker. 
 
To further investigate the potential of the new methodology in the target 
discovery, we analyzed the entire sub-proteome selected by our probe.  
To this end, the coomassie stained gel (both SLD-AZ and controls gel lanes) 
(Figure 48) was subjected to in situ protein digestion, the peptide mixtures 
were analysed through nano-flow LC-MSMS and the proteins identified by 
database search using the Mascot server.  
The resulting SLD-AZ interacting target(s) list was refined by removing the 
hits shared with the control experiments, thus obtaining a list of approximately 
90 proteins. The identified proteins were clustered through the STRING 
software (http://string-db.org/) to give the network of the functional complexes 
binding SLD in vivo.  However, as also reported by Cravatt and co-
workers[180], we experienced that this methodology suffers of a high 
background, probably due to  high amounts of  low-affinity abundant proteins.  
Nevertheless, looking at the STRING output (Figure 48), a key correlation 
appears between PRDX1, located  at the centre of a large protein network, and 
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both the 14-3-3 isoforms and the proteasome machinery, the latter a target also 
detected in the in vitro pull down, even if as a minor interactor. 
 
 
Figure 48. 12% SDS-PAGE of proteins eluted from in cell fishing for partners of SLD and 
control pull-down. Interactions network obtained clustering proteins identified as SLD targets 
in HeLa living cells 
  
This last evidence was confirmed by western blotting. The proteins eluted 
from SLD-AZ and control experiments were blotted with monoclonal 
antibodies against the α-7 subunit, a component of 20S proteasome, and 
Psmc3, a proteasome regulator. As reported in figure 49, the blotting showed 
a substantial enrichment of both proteins only in the samples containing SLD-
AZ and the whole catalytic mixture.  
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Figure 49. Proteins eluted from control and SLD-beads after in cell pull down were 
transferred onto nitrocellulose membrane and probed with antibodies anti-proteasome alpha 7 
subunit and  anti-PSMC3 
 
Reported results indicate that we have successfully optimized an in cell pull 
down LC-MS/MS methodology based on the click-chemistry copper-catalysed 
variant of the Huisgen 1,3-dipolar cycloaddition for the interactome profiling 
of the anti-inflammatory marine metabolite scalaradial. The concurrent 
definition of its in vitro profiling helped as reference point for the validation of 
the in cell procedure. We obtained a list of cellular potential targets and, 
among them, PRXs, 14-3-3 isoforms and proteasome were selected as relevant 
SLD partners on the basis of their involvement in the inflammatory process. 
These targets, then validated by SPR and western blotting analyses, are 
functionally connected to the PI3K and NF-κB pathways already known to be 
modulated by SLD[186-190]. 
 
4.4 In-Cell Oleocanthal Proteome Profiling  
 
The effectiveness of the click chemistry-based in cell proteome profiling 
technique was assessed applying the above-mentioned approach to another 
compound, Oleocanthal (OLC). This olive-oil phenolic component is known 
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to interfere with different pathways of relevant human diseases, such as 
inflammation[193] and Alzheimer’s disease[194-198]. OLC had been already 
studied through the classical in vitro AP-MS approach, demonstrating its 
highly specific binding with the molecular chaperone HSP90. More in details, 
HSP90 was identified as OLC main target in two cell lines (HeLa and U937), 
and  several independent assays showed the OLC ability to covalently bind 
HSP90 and inhibit its chaperone activity, with a significant reduction of Akt 
and Cdk4 levels. Moreover, OLC was also able to modulate the HSP90 
supramolecular arrangement, stimulating the formation of high molecular 
weight structures[133].   
The azide-OLC derivative was synthesized (Figure 50) and  incubated with a 
sample of HeLa cells. 
 
Figure 50. OLC coupling reaction with TRX-AZ and mass spectrometric analysis of obtained 
product. MS spectrum shows the MH+ ion of the piperidinic OLC-TRX adduct and MSMS 
 
spectrum shows the diagnostic loss of ethylene and ethyl azide. 
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The reaction of OLC with TRX-AZ was performed in ACN/NaHCO3 for 30 
minutes at r.t. using a ten-fold molar excess of the azide linker. The Schiff 
base intermediate, produced by the condensation of the terminal amino group 
on TRX-AZ and one of the OLC aldehyde carbonyls, was reduced with 
NaBH4,  giving rise to a stable piperidine adduct, purified by HPLC-UV and 
characterized by LC-MSMS (Figure 50). 
HeLa cells were then treated with 100 µM OLC-AZ or TRX-AZ and, after 
three hours of incubation, supernatants were discarded and cells were 
harvested with PBS and gently lysed by homogenation. 
The modified Huisgen’s cycloaddition reaction was carried out for 45 minutes 
in presence of 100 µM CuSO4, 5 mM Na-Ascorbate and 100 µM TBTA. The 
OLC interactors were finally eluted and analysed by western blotting using an 
anti-HSP90 antibody. The resulting chemiluminescence signal intensities, 
reported in figure 51,  revealed the ability of the OLC-AZ probe to recruit its 
main cellular interactor.   
 
 
 
 
Figure 51. Western blotting on proteins enriched in cell by OLC and TRX-AZ using an anti 
Hsp90 antibody. 
 
The gathered results confirm that the Huisgen’s cycloaddition in vivo chemical 
proteomics approach is an effective tool to allow the molecular recognition 
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step to take place in living cells leading to the isolation of a large set of sub-
proteomes. This feature could represent an interesting strength point of the 
technique, allowing a more comprehensive analysis of the interactomic profile 
of a small molecule. On the other hand, this could hamper an easier selection 
of the more likely physiological relevant potential partners.    
 
 
Results and Discussion 
 
 
- 92 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Results and Discussion 
- 93 - 
 
 
 
 
  
 
-CHAPTER 5- 
 
 
New insights in the cCMP interaction profile by chemical 
proteomics. 
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5.1 Background 
 
The purine cyclic nucleotides 3',5'-cyclic adenosine monophosphate (cAMP) 
and 3',5'-cyclic guanosine monophosphate (cGMP) play a pivotal role in the 
cellular context, acting as second messengers and mediating the cellular 
effects of a wide range of  hormones and neurotransmitters[199,200]. Beside the 
natural existence of 3’-5’-cyclic cytidine monophosphate (cCMP) has been 
controversially debated [201-207], recent evidences have confirmed that many 
cell types contain cCMP at micromolar concentrations[208]. Moreover, several 
experiments have been performed to evaluate the ability of cCMP to cross-
activate the cAMP and cGMP dependent protein kinases. Particularly, cCMP 
was found to relax aortic smooth muscle and inhibit platelet aggregation by 
activating cGMP dependent protein kinases[209], and its functional interaction 
with HCN channels was also examined[210]. Furthermore, Rab23 was identified 
as the first protein selectively phosphorylated in response to cCMP[211].  
Nevertheless, a specific cCMP receptor has not yet been identified and the 
only attempt to analyse the cCMP interactome led to the exclusive 
identification of PKA as main molecular target[212]. 
Chemical proteomics has been demonstrated to be a powerful tool for the 
isolation of PKA and PKG related sub-proteomes. Moreover, the employment 
of cAMP- and cGMP-bearing matrices drove to the discovery of new AKAPS, 
unravelling many aspects of the cyclic nucleotides related cellular response[213-
215]
.   
Therefore, an affinity chromatography approach was chosen to disclose 
potential new macromolecular target(s) of cCMP. 
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5.1 Fishing out cCMP interactors 
 
Although the occurrence of cCMP has been proved in multiple cell lines, the 
physiological relevance of this cyclic nucleotide has not been clarified yet. 
Aiming at the analysis of the comprehensive interactome of this potential 
second messenger, we developed a chemical proteomics approach using 
cCMP as a bait. An analogue of cCMP endowed with a six carbons spacer 
arm, N4-(6-Aminohexyl)cytidine-3',5'-cyclic monophosphate (4-AH-cCMP), 
was immobilized onto agarose beads and used as a bait to fish out its 
biological targets (Figure 52). 4-AH-cCMP was put in reaction with NHS-
activated beads and the reaction yield was evaluated by means of RP-HPLC-
UV. Comparing the peak areas of 4-AH-cCMP at the beginning and after 16h 
of reaction, a 30% yield was assessed, and the final concentration of cCMP 
was estimated  to be 3 µmol/ml resin.  
 
 
 
 
Figure 52. Reaction scheme of cCMP immobilization onto NHS activated agarose beads. 
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The residual free reactive groups on the beads surface were quenched applying 
a solution of a primary amine (2-Amino-2-hydroxymethyl-propane-1,3-diol). 
Moreover, control beads were also prepared treating an NHS-activated agarose 
sample directly with the amine solution.  
Control beads and cCMP-beads were then incubated with a HEK293 cellular 
lysate, keeping the suspension under gentle shaking for 1 hour at 4°C. 
Subsequently, the unbound proteins were discarded and both matrixes were 
subjected to several washing with a saline buffer containing a small quantity 
of surfactant to minimize the background amount. The tightly bound proteins 
were finally eluted by means of a denaturing buffer and subjected to 1D-gel 
electrophoresis. The coomassie-stained protein bands were cut out, digested, 
and analysed by nanoLC tandem mass spectrometry. Only proteins highly 
enriched by cCMP, compared with control, were taken into account. cAMP 
and cGMP macromolecular effectors, such as PKA and PKG, were found 
along with other secondary interactors of these proteins (AKAPS) (Figure 53).  
 
 
 
Figure 53. Table of cCMP interactors belonging to purine cyclic nucleotides dependent 
pathway. 
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The chemical structure of the cyclic portion of cCMP resembles the structure 
of the most common cyclic nucleotide cAMP and cGMP, and this could 
account for the enrichment of all the isoforms of PKA and PKG regulatory 
subunits. These findings are in agreement with previous studies reporting the 
ability of cCMP to activate PKG in platelet aggregation and in smooth muscle 
relaxation[209].  
In order to obtain a more focused list of cCMP specific interactors, a 
competition experiment was also developed pre-incubating different batches 
of cellular lysate with cyclic and not cyclic nucleotides, such as adenosine 
diphosphate (ADP), guanosine diphosphate (GDP), cAMP and cGMP (Figure 
54).  
 
 
Figure 54. Schematic representation of competition assay coupled to PSMs quantization for 
cCMP interactome definition. 
 
This is a common procedure, reported in literature, useful to eliminate 
interactors shared between cyclic and acyclic nucleotides[214,215]. More in 
details, the competition experiments were performed adding to the cellular 
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lysate ADP and GDP; (ii) ADP, GDP and cAMP (iii) ADP, GDP and cGMP 
(iv) ADP, GDP, cAMP, cGMP (as reported in experimental section), and 
comparing the proteins enriched from the bait in the absence and in presence 
of the other nucleotides. In parallel, a control experiment was carried out to 
subtract background proteins.  
The electrophoretic profiles, reported in Figure 55, show the ability of ADP 
and GDP to compete for the interaction of PKA and PKG regulatory subunits 
with the anchored cCMP. These findings suggest a cCMP weak affinity for 
these proteins. 
 
 
 
Figure 55. Coomassie stained SDS-PAGE obtained from competition experiments illustrating 
as new protein bands became evident in presence of non-cyclic nucleotides and persist also in 
presence of cAMP and cGMP.  
   
Notably, in presence of ADP and GDP  in the incubation mixture, new bands 
were observable after the coomassie staining, that were also visible when 
cAMP and cGMP were added to the mixture, indicating the presence of 
specific cCMP interactors.  
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The gel lanes portions framed with black boxes (Figure 55) were cut in small 
pieces, in situ digested and analysed by nanoLC-MSMS, giving the protein 
identification. A semi-quantitative estimation of the abundance of each protein 
in all the experimental conditions was also assessed comparing their number 
of PSMs (Peptide spectral matches), to weigh the specificity of the interaction. 
Only proteins whose binding to cCMP-matrix was not competed by the 
presence of other nucleotides were considered as potential specific interactors. 
Moreover proteins identified with less than five PSMs were discarded, in order 
to obtain highly confident results. Interestingly, several proteins belonging to 
the heterogeneous nuclear ribonucleoproteins class were considerably 
enriched, in presence of both ADP and GDP in the incubation mixture (Figure 
56).  
 
Figure 56. Table shows proteins whose ability to bind cCMP-bearing matrix is increased in 
presence of ADP and GDP and the ratio between counted PSMs 
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The ability of non-cyclic nucleotides to prevent the binding of PKA and PKG 
to cCMP indicate a low affinity interaction. On the other hand, the occurrence 
of the heterogeneous nuclear ribonucleoproteins only in presence of ADP and 
GDP in the protein mixture suggests that these proteins should be considered 
as secondary cCMP partners. However, the biological role of this interaction 
could be of interest, although the apparent low affinity between the 
counterparts, since several cellular pathways are modulated through weak 
interactions[9]. Indeed, the binding of cCMP to heterogeneous nuclear 
ribonucleoproteins may be functionally relevant in the cellular environment, 
opening the way to new studies on unexplored roles for cytidine derived cyclic 
nucleotide. 
 
 
 
 
 
 
 
 
 
Conclusions 
 
 
- 102 - 
 
 
Conclusions 
 
 
- 103 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions
 -CHAPTER 6-
Conclusions 
 
 
- 104 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
 
- 105 - 
 
Conclusions 
 
Several bioactive small molecules explicate their activity through protein 
modulation. One of the main issues in the field of pharmaceutical science is 
the discovery of new compounds endowed with intriguing pharmacological 
profiles and virtually free of side effects. Indeed, although medicinal 
chemistry spends many efforts in designing highly specific compounds, a lot 
of them share a multi-target interaction profile[9].  
The natural environment represents one of the main source of new therapeutic 
agents[137]. In particular, marine drugs are endowed with intriguing chemical 
structures, often responsible for their relevant biological activities. The 
translation of a biological effect in a therapeutically useful drug requires a 
comprehensive knowledge of its biological profile. Chemical proteomic 
approaches offer the peculiar chance to investigate the entire interactome of a 
small molecules in a single experiment and in an unbiased fashion[9]. Due to 
the high feasibility demonstrated by affinity chromatography coupled to mass-
spectrometry in identifying physiologically relevant drug-targets[117-119], an 
AP-MS approach has been optimized to fish out the specific targets of some 
secondary metabolites from marine sources, Suvanine, Heteronemin and 
Scalaradial.  
Suvanine (SUV) is a tricyclic bioactive sesterterpene endowed with an anti-
inflammatory activity, isolated from different specimens of Coscinoderma 
sponges[141]. Coscinoderma genus is a rich source of sulfated terpenoids, often 
exhibiting valuable biological effects. SUV and its derivatives were found to 
inhibit in vitro different secretary phospholipases (sPLA2) and to reduce NO 
and prostaglandin E2 (PGE2) production[141].  
By means of an MS-based affinity chromatography approach, HSP60 has been 
identified as the main biological target of SUV in HeLa cells. The specificity 
of the interaction between SUV and HSP60 was assessed by western blot 
analysis and was also validated by surface plasmon resonance and pull down 
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assays using the recombinant protein. A low micro-molar dissociation constant 
(0.6±0.5 µM) of the SUV-HSP60 complex was measured by SPR, suggesting 
a strong interaction. This interaction might give evidence of the suvanine anti-
inflammatory potential, because of the involvement of this molecular chaperon 
in the inflammatory response. On this basis,  the ability of SUV in inhibiting 
HSP60 activity was demonstrated by an in vitro assay. Since the mammalian 
HSP60 plays an important role during chronic inflammation and 
atherosclerosis[150], SUV could be considered a candidate lead compound for 
the rational design of novel HSP60 inhibitors[121].  
The above procedure was also applied to the marine sesterterpene 
Heteronemin (HET). HET was isolated from the sponge Hyrtios erecta[157] and 
was found to inhibit proteasome machinery in K562 cells[158]. The interaction 
with the proteasome subunit was confirmed also in our chemical proteomics 
experiment. Surprisingly, along with the proteasome we recovered TDP43 that 
was recognized, on the basis of the experimental data, as the main cellular 
partner of HET in HeLa cells. These results were confirmed by western blot 
and surface plasmon resonance experiments, that gave a dissociation constant  
of 270±200 nM. TDP43 is considered an “hot target” in pharmaceutical 
research, due to its involvement in several neurodegenerative diseases. 
Actually, TDP43 has an high tendency to aggregate[163] generating inclusions 
that are often found in neurodegenerative disorders[164]. On this basis, we have  
investigated the HET modulation of TDP43 aggregation both in vitro and in 
vivo. TDP43 gave rise to the formation of high molecular aggregates and was 
revealed to translocate from nucleus to cytoplasm upon HET treatment, and to 
localize in stress granules upon heat shock co-treatment . Using alpha screen 
technology, HET was also shown to decrease TDP43 affinity toward its 
cognate DNA, the oligonucleotide TAR32, with an IC50 of 10 nM (±0.5)[216]. 
By using a similar approach, the interactome of Scalaradial, a 
sesterterpenoidic molecule with a scalarane-skeleton, isolated[184,185] from the 
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sponge Cacospongia mollior, was disclosed. SLD was found to bind proteins 
belonging to the 14-3-3 and peroxiredoxin classes. The interaction with 
Peroxiredoxin 1 (PRX1) and 14-3-3 ε was further confirmed by SPR, showing 
a high affinity towards both proteins. 
A new approach based on bio-orthogonal chemistry has also been optimized to 
investigate the interaction profile of small molecules directly in a living 
systems. By using copper-catalyzed azide-alkyne cycloaddition, scalaradial, 
conveniently decorated, was anchored to a solid support and its 
macromolecular partners were then characterized. Thus, the previously found 
interactions of SLD with 14-3-3 and PRX1 were confirmed in living HeLa 
cells, and the bio-orthogonal reaction was proved as valuable mean for in cell 
fishing for partners approach. Analysis of the whole SLD proteome gave a set 
of new protein complexes. This feature could represent a key factor of this 
technique, allowing a more comprehensive analysis of the interactome profile 
of a small molecule, even if, on the other hand, could hamper the selection of 
the relevant physiological partner(s). Moreover, we experienced that this 
methodology suffers of a higher background signal, probably due to a higher 
amount of low affinity interactions with abundant proteins.   
The above methodology was also applied to Oleocanthal, as further  
confirmation on the effectiveness of this approach. OLC ability to bind and 
modulate HSP90 activity was confirmed[190].   
 In a last study, chemical proteomics was applied to the investigation of cyclic 
nucleotides-related cellular response, in particular using cCMP (3’-5’-cyclic 
cytidine monophosphate) as a bait. The cCMP interactome was deeply 
investigated by means of competition experiments, and a list of 
macromolecular partners was obtained, containing, along with the well known 
PKA and PKG, also new interactors belonging to the heterogeneous nuclear 
ribonucleoproteins family. 
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In vitro and in cell chemical proteomics on marine 
compounds target discovery : Experimental procedures 
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7.1 Suvanine target discovery 
 
7.1.1 Synthetic procedure to obtain suvanine-aldehyde 
 
A solution of SUV (15 mg, 0.033 mmol) in pyridine (0.5 mL) and dioxane 
(0.5 mL) was heated at 150°C for 2.5 h in a reaction vial. After the solution 
was cooled, the mixture was evaporated to dryness, and then purified by 
HPLC on a m-Bondapak C18 column (30cm x 3.9 mm; Waters) with 
MeOH/H2O (80:20) to give aldehyde as a mixture of two diastereoisomers 
(9.2 mg, 80%).  
 
 
7.1.2 Generation of the suvanine functional matrix 
 
CDI activated beads  (Pierce, Rockford, IL)  (0.2 mL)  were treated with 4 
µmol 4,7,10-trioxa-1,13-tridecanediamine (Sigma-Aldrich) (NH2(PEG)3NH2) 
dissolved in NaHCO3 (50 mM) with CH3CN (30%) at pH 8.5 and incubated 
for 16 h at room temperature with continuous shaking. Then, to verify the 
presence of free amine groups on the modified matrix  surface, beads were 
washed with ethanol and subjected to a Kaiser test[217]. The obtained amine 
beads were then treated with SUV-AL (1.5 mg) dissolved in CH3CN (400 µL), 
NaHCO3 (30%, 50 mM) at pH 8.0. The reaction mixture was kept for 16 h at 
room temperature under continuous shaking and the amount of immobilized 2 
was estimated by integrating the peaks of the free SUV-AL species after 
HPLC injections of supernatants at t=0, 2, and 16 h, in an 1100 Series 
chromatographer (Agilent). 
HPLC runs were carried out on a C4 column (250 x 2.0 mm; Phenomenex, 
Torrance, CA) at a flow rate of 200 mLmin-1. The gradient (solution A: TFA 
(0.1%); solution B: TFA (0.07 %), H2O (5%), CH3CN (95 %)) was 10–95% B 
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over 45 min. The same experimental conditions were applied for the 
preparation of the control matrix. Briefly, activated CDI-Agarose support (200 
µL) was mixed with acetylated NH2(PEG)3NH2 (4 µmol) dissolved in 
NaHCO3 (50 mM) containing CH3CN (30%) at pH 8.5. The matrices were 
stored at 4°C in acetone.  
 
 
7.1.3 Affinity purification and identification of Suvanine partners 
 
HeLa cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with fetal bovine serum (10% (v/v)), penicillin (100 UmL-1), 
streptomycin (100 mgmL-1),  glutamine (4 mM), HEPES (10 mM), and 
sodium pyruvate (10 mM)  at 37°C in a 5% CO2 atmosphere (all reagents from 
Sigma–Aldrich). The cells were collected by centrifugation (10000 rpm, 3 
min) and washed three times with phosphate saline buffer (PBS; sodium 
phosphate (50 mM), NaCl (150 mM), pH 7.5). The obtained pellet was 
dissolved in 1 mL ice-cooled PBS containing  Igepal  (0.1%) and glycerol 
(5%) and supplemented  with protease inhibitor cocktail. The obtained 
solution was sonicated for 2 min in a Vibra-Cell (amplitude 30%; Sonics, 
Newton, CT) and clarified by centrifugation (10000 rpm, 10 min, 4°C). 
The  supernatant  was collected, and  the protein concentration was tested with 
a Bradford assay[218] and adjusted to 1 mgmL-1.  
SUV-bound beads suspension (50 µL) and the same amount of the control 
matrix were separately incubated with HeLa total protein preparation (1 mg) 
under continuous shaking (16 h, 4°C). The beads were precipitated by 
centrifugation  (1200 rpm, 3 min, 4°C) and washed six times with PBS (pH 
7.4). The bound proteins were eluted by boiling the beads in SDS-PAGE 
sample buffer (Tris·HCl 60 mM, pH 6.8 with 2% SDS, 0.001 % Bromophenol 
Blue, 10% glycerol, 2% 2-mercaptoethanol). The eluted proteins were 
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separated on 12% SDS-PAGE, and stained with G-250 Coomassie stain (Bio-
Rad, Hercules, CA).  
 
 
7.1.4 Suvanine interactome identification  
 
Each SDS-PAGE gel lane from control and  suvanine-based experiments was 
cut in ten pieces. Each piece was washed with ultrapure water and CH3CN and 
subjected to in situ protein digestion as described by Shevchenko[146]. Briefly, 
each slice was reduced with 1,4-dithiothreitol (DTT, 10 mM) and alkylated 
with iodoacetamide (50 mM), then washed and rehydrated in trypsin solution 
(12 ngmL-1) on ice for 1 h. After the addition of ammonium bicarbonate (30 
µL, 10 mM, pH 7.5), protein digestion was allowed to proceed overnight at 
37°C. Supernatants were collected and peptides were further extracted from 
gel slices using 100% CH3CN. Finally, second supernatants were collected 
and combined with first ones. Peptide samples were dried and dissolved in 
formic acid (FA, 10%) before MS analysis. Peptide mixtures (5 µL) were 
injected into a nano-ACQUITY UPLC system (Waters) and separated on a 1.7 
mm BEH C18 column (Waters) at a flow rate of 400 nLmin-1. Peptide elution 
was achieved with a linear gradient (solution A: H2O (95 %), CH3CN (5 %), 
FA (0.1%); solution B: CH3CN (95 %), H2O (5 %), FA (0.1 %)); 15–50% B 
over 55 min). MS and MS/MS data were acquired with a Q-TOF Premier mass 
spectrometer (Waters). The five most intense doubly and triply charged ions 
were chosen by MassLynx software (Waters) and fragmented. The resulting 
MS data were processed by ProteinLynx (Waters) software to generate peak 
lists for protein identifications. Database searches were carried out on the 
Mascot server (http://www.matrixscience.-com/). The SwissProt database 
(release 2012_03, 21 March 2012, 535248 sequence entries, 189901164 amino 
acids abstracted from 208076 references) was employed (settings: two missed 
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cleavages; carbamidomethyl (C) as fixed modification and oxidation (M) and 
phosphorylation (ST) as variable modifications; peptide tolerance 80 ppm; 
MS/MS tolerance 0.8 Da). 
 
 
7.1.5 In vitro validation of HSP60–suvanine interaction  
 
Human recombinant HSP60 (Enzo Life Science, Framingham, NY) at the 
concentration of  0.18 mM was incubated with immobilized suvanine-beads 
(20 µL) in PBS buffer for 1 h at 4°C followed by gentle mixing. Several PBS 
washing steps were performed, and the bound protein was eluted by addition 
of SDS sample buffer to the beads. As negative control, the same amount of 
HSP60 was incubated with control beads. Similar pull-down experiments were 
performed by pre-incubating HSP60 with and without SUV or SUV-AL (20 
and 100 µM) in PBS buffer for 1 h at 4°C followed by gentle mixing, and the 
mixtures were added to suvanine-modified beads (20 µL). Several washing 
steps were performed with PBS and the bound protein was eluted by addition 
of SDS sample buffer to the beads. All samples were analyzed by SDS-PAGE 
(12%), and proteins were stained with Coomassie stain. Then, suvanine-
modified beads suspension (50 µL) and the same amount of the control matrix 
were treated as above (see affinity purification step) and the eluates were 
analysed by Western blotting. Briefly, each sample was resolved on a 12% 
SDS-PAGE gel, and transferred onto a nitrocellulose membrane. The 
membrane was incubated for 1h in a blocking solution containing Tris (25 
mM, pH 8), NaCl (125 mM), Tween-20 (0.05 %), and nonfat dried milk 
powder (5%), then incubated overnight at 4°C with primary monoclonal 
antibodies raised against HSP60 (BD Biosciences), HSP70 (Enzo Life 
Science) and HSP90 (BD bioscience), at dilutions of 1:2000, 1:1000, and 
1:1000, respectively. Finally the membranes were incubated for 1 h with 
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mouse peroxidase-conjugated secondary antibody (1:5000; Thermo 
Scientific). HSPs were detected by using the Amersham enhanced 
chemiluminescence (ECL) detection system (GE Healthcare). 
 
 
7.1.6 HSP60–suvanine binding affinity by surface plasmon resonance 
 
HSP60 was immobilized onto a CM5 sensor chip by using standard amine 
coupling procedures. Phosphate buffered saline (10 mM Na2HPO4, NaCl 150 
mM, pH 7.4) was used as running buffer. The carboxymethyl dextran surface 
was activated with a 5 min injection of a 1:1 ratio of EDC and NHS (100 mM 
at 5 µLmin-1). HSP60 was diluted to 30 ngmL-1 in sodium acetate (10 mM, pH 
4.5) and injected onto the activated chip surface (flow rate 5 µLmin-1). Protein 
concentration was adjusted to obtain an optimal response (~15 000 RU). 
Remaining active groups were blocked with a 7 min injection of 
ethanolamine·HCl (1.0 M, pH 8.5) at 5 µLmin-1. For these biosensor 
experiments, SUV and SUV-AL (0.5–5 µM) were diluted in PBS containing 
2% DMSO. Each concentration was tested at least three times. As they 
dissociated to baseline within a reasonable time, no regeneration was required 
among injections. The interaction experiments were carried out at a flow rate 
of 10 µLmin-1 over a 3 min injection time. The dissociation time was set at 
600s. Rate constants for association (ka), dissociation (kd) and the dissociation 
constant (KD) were obtained by globally fitting data from all the injection of 
different concentrations of each compound by using BIAevaluation software 
(GE Healthcare) with a simple 1:1 Langmuir binding model.  
 
7.1.7 Suvanine inhibition of HSP60 chaperone activity 
 
Active citrate synthase (CS) catalyses the following reaction: 
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acetyl-CoA + oxalacetate  H2O + citrate + CoA-SH 
 
As 5,5’-di-tio-bis-2-nitrobenzoic acid (DTNB) was added in the mixture, 
CoA-SH undergoes the following reaction: 
 
CoA-SH + DTNB  TNB + CoA-S-S-TNB 
 
CoA-S-S-TNB formation can be easily measured at 412 nm. CS (Sigma-
Aldrich) was incubated  at 15 µM in buffer (Tris·HCl (100 mM, pH 8), 
guanidine·HCl (6M), DTT (20 mM)) for 2h at room temperature. This solution 
was then diluted (1:100) in renaturing buffer (Tris·HCl (50 mM, pH 7.5), 
MgCl2 (10 mM), KCl (10 mM)) at 35°C in the presence or absence of (human) 
HSP60/HSP10 complex and at different concentrations of SUV and SUV-AL. 
For this, CS was incubated with HSP60 (3 µΜ), HSP10 (2 µΜ), and ATP (2 
µΜ) with or without SUV and SUV-AL (3–150 µΜ) as follows: SUV and 
SUV-AL were first incubated with HSP60 (30 min, 4°C), then HSP10 was 
added and incubated (30 min, 4 °C), and finally CS refolding was started by 
addition the obtained complex and ATP at 35°C. Several incubations were 
performed to test for possible direct effects of SUV or SUV-AL on CS 
renaturation by allowing CS refolding at 25°C in absence of HSP60/HSP10 
with and without SUV and SUV-AL (32 and 160 µM) under the same 
conditions. Colorimetric measurements were performed  after 3h of incubation 
at 35°C with stirring. Each solution (20 µL) was diluted in Tris·HCl (1 mL, 50 
mM, pH 8) with EDTA (2 mM), oxalacetic acid (0.1 mM), DTNB (0.1 mM), 
and acetyl-CoA (0.15 mM), and absorbance was measured at 412 nm 
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2.00 mm, Phenomenex, Torrance, CA) at a flow rate of 0.200 mLmin-1. 
Elution was achieved by means of a linear gradient of B from 10 to 95% over 
25 min (solution A: H2O and TFA (0.1%); solution B: MeCN and TFA 
(0.1%)). 
Both resins were washed 3 times with 1 mL of phosphate saline buffer and 
then incubated with a mixture of water/isopropanol (1:2) for 4 h at room 
temperature to inactivate the free epoxy-groups. Then, matrices were washed 
extensively with PBS to remove traces of isopropanol and stored at 4°C in 
PBS 30% ethanol. 
 
 
7.2.2 Affinity purification and identification of HET partners 
 
HeLa cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 
mg/ml streptomycin, at 37°C in a 5% CO2 atmosphere (all reagents were from 
7.2 HET target discovery 
 
7.2.1 Generation of the HET functional matrix 
 
Epoxy-activated Sepharose™ 6B matrix was swollen with water (200 µL/mg) 
for 60 min and extensively washed with water.  
HET (2 mg, 4,1 µmol) was diluted in 450 µL of 78% MeCN/ 22% NaHCO3 at 
pH 8.0 and added to 200 µL of matrix at room temperature for 2.5 hours with 
continuous shaking. A control matrix was obtained in the same experimental 
conditions without the marine metabolite. The amount of immobilized HET 
was estimated by integrating the peaks of the free HET after HPLC injections 
of supernatants at t=0 and 2.5 h in a 1100 Series Chromatographer (Agilent). 
HPLC runs were carried out on a C18 column (Jupiter  Proteo C18 5µ  250 x 
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Sigma–Aldrich). Cells were collected by centrifugation (10000 rpm, 5 min), 
washed three times with PBS and re-suspended in 1X ice cooled PBS 
containing Igepal (0.1%), supplemented with a protease inhibitor cocktail. The 
obtained suspensions were sonicated for 2 min with Vibracell (Sonics) setting 
an amplitude of 30% and cellular debris were removed by centrifugation at 
10000g for 10 min at 4 °C. Protein concentration was determined using 
Bradford assay and adjusted to 1 mg/ml. HET-bound bead suspension (50 µL) 
and the same amount of the control unbound matrix were separately incubated 
with 1 mg of HeLa extract under continuous shaking (16 h, 4°C). The beads 
were collected by centrifugation (1200, 1 min, 4°C) and washed six times with 
PBS (pH 7.4). The bound proteins were eluted by boiling the beads in SDS-
PAGE sample buffer (60 mM Tris/HCl pH 6.8, 2% SDS, 0.001% 
bromophenol blue, 10% glycerol, 2% 2-mercaptoethanol). The eluted proteins 
were separated on 10% SDS-PAGE, and stained with Coomassie G-250 (Bio-
Rad, Hercules, CA). 
 
 
7.2.3 HET partners identification 
 
Three bands from SDS-PAGE gel lane relative to the HET-based and control 
experiments were cut and digested. The experiment has been repeated three 
times using an opportune control matrix bearing the linker without any 
metabolite. Each piece was washed with ultrapure water and CH3CN and 
subjected to in situ protein digestion as described by Shevchenko[146]. Briefly, 
each slice was reduced with 10 mM 1,4-dithiothreitol (DTT) and alkylated 
with 54 mM  iodoacetamide, then washed and rehydrated in trypsin solution 
(12 ng/mL) on ice for 1 h. After the addition of ammonium bicarbonate (30 
µL, 50 mM, pH 7.5), proteins digestion was allowed to proceed overnight at 
37°C. The supernatant was collected and peptides were extracted from the 
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slice using 100% CH3CN and both supernatants were combined. The peptide 
samples were dried and dissolved in formic acid (FA, 10%) before MS 
analysis. The peptide mixture (5 µL) was injected into a nano-ACQUITY 
UPLC system (Waters). Peptides were separated on a 1.7 mm BEH C18 
column (Waters) at a flow rate of 400 nL/min. Peptide elution was achieved 
with a linear gradient (solution A: 95 % H2O ,5 % MeCN, 0.1% FA; solution 
B: 95 % MeCN, 5 % H2O, 0.1 % FA); 15–50% B over 55 min). MS and 
MS/MS data were acquired with a Q-TOF Premier mass spectrometer 
(Waters). The five most intense doubly and triply charged peptide ions were 
chosen by MassLynx software (Waters) and fragmented. The resulting MS 
data were processed by ProteinLynx (Waters) software to generate peak lists 
for protein identifications. Database searches were carried out on the Mascot 
server (http://www.matrixscience.com/). The SwissProt database (release 
2012_03, 21 March 2012, 535248 sequence entries, 189901164 amino acids 
abstracted from 208076 references) was employed (settings: two missed 
cleavages; carbamidomethyl (C) as fixed modification and oxidation (M) and 
phosphorylation (ST) as variable modifications; peptide tolerance 80 ppm; 
MS/MS tolerance 0.8 Da). 
 
 
7.2.3 In vitro validation of TDP43–HET interaction 
 
HET-modified beads suspension (50 µL) and the same amount of the 
unmodified matrix were treated as described above and the eluates were 
analyzed by Western blotting. Briefly, each sample was resolved on a 10% 
SDS-PAGE gel, and transferred onto a nitrocellulose membrane. The 
membrane was incubated for 1 h in a blocking solution containing 25 mM Tris 
pH 8, 125 mM NaCl, 0.1% Tween-20, 5% non-fat dried milk, then incubated 
overnight at 4°C with primary monoclonal antibody raised against TDP43 
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(Sigma-Aldrich) at 1:8000 dilution. Membranes were then incubated for 1 h 
with rabbit peroxidase-conjugated secondary antibody (1:5000; Thermo 
Scientific). TDP43 was detected using an enhanced chemiluminescent 
substrate (ECL) and LAS 4000 (GE Healthcare, Waukesha, WI, USA) digital 
imaging system. 
 
 
 
7.2.4 TDP43–HET binding affinity by surface plasmon resonance 
 
TDP43 was immobilized onto a CM5 sensor chip by using standard amine 
coupling procedures using PBS as running buffer. The carboxymethyl dextran 
surface was activated with a 5 min injection of a 1:1 ratio of EDC and NHS 
(100 mM at 5 µL/min). TDP43 was diluted to 30 ng/µL in potassium acetate 
(10 mM, pH 4.5) and injected onto the activated chip surface (flow rate 5 
µL/min) until reaching ~16 000 RU. Remaining active groups were blocked 
with a 7 min injection of ethanolamine·HCl (1.0 M, pH 8.5) at 5 µL/min. For 
these biosensor experiments, HET (0.01–25 µM) was diluted in PBS 
containing 1% DMSO. Each concentration was tested at least three times. The 
interaction experiments were carried out at a flow rate of 10 µL/min over a 3 
min injection time. The dissociation time was set at 600 s. Rate constants for 
association (ka), dissociation (kd) and the dissociation constant (KD) were 
obtained by globally fitting data from all the injection of different 
concentrations of each compound by using BIAevaluation software (GE 
Healthcare) with a simple 1:1 Langmuir binding model. The same experiment 
was carried out immobilizing the following proteins that didn’t bind HET: 
Heat Shock Protein 90 and bovine serum Albumin. 
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7.2.5 In vitro effect of HET on TDP43 aggregation 
 
TDP-43 stock solution (25 µM in 33% glycerol, 80 mM Tris-HCl, 0.1% SDS 1 
mM DTT) was diluted in 1:500 in PBS containing 2 mM DTT and 5% 
glycerol at a final concentration of  50 nM and incubated with a 50 molar fold 
of HET.  Since the small molecule was withdrawn from 50X stock solutions in 
DMSO, a control experiment was performed adding an equal amount of 
DMSO to protein solution. Samples were then subjected to agitation (1200 
rpm) for 15 minutes and centrifuged for 30 min at 16000 g;  pellets and 
supernatants were carefully separated and a solution of 8 M urea and 2 M 
thiourea was added to each sample to reach a final concentration of 2.6 M 
Urea and 0.67 M thiourea. Following 10 min of incubation on ice, 10 µL of 
each sample was diluted with 5 µL of loading buffer and ran on a 10% SDS-
PAGE. Western blotting analysis was then performed as reported above. 
 
 
7.2.6 Alpha-screen assays to monitor TDP43 binding to bt-TAR32-DNA 
 
TDP-43 with a glutathione S-transferase (GST) tag on the C-terminus was 
purchased from Abnova. Single-stranded DNA oligonucleotide (TAR32) 
biotinylated (bt) at the 5′ end, was synthesized by LifeTechnologies . The 
TAR-32 sequence is 5′-CTG CTT TTT GCC TGT ACT GGG TCT CTG TGG 
TT-3′ and corresponds to the first 32 nucleotides of the sequence identified by 
Ou et al. to bind to TDP-43[160].  AlphaScreen GST detection kit was 
purchased from PerkinElmer. Different concentrations of bt-TAR-32 and 
GST-TDP43 were tested to optimize measurements. Finally, assay mixtures 
contained TDP-43 at final concentration of  0.1 nM, bt-TAR-32 5 nM, 10 
µg/mL of AlphaScreen streptavidin donor beads and  anti-GST acceptor beads 
diluted in assay buffer (25 mM Tris [pH 7.4], 0.1% chaps).  More in details, 
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TDP-43 (0.2 nM) was pre-incubated with 20 µg/mL anti-GST acceptor beads 
in assay buffer for 30 min at room temperature and then added to assays 
containing 10 nM bt-TAR-32 also pre-incubated with 20 µg/mL streptavidin 
donor beads for 30 min at room temperature. Later on, acceptor and donor 
beads were combined in 384-well plates. After 3 h of  incubation in the dark at 
room temperature, to ensure the binding reaction was at equilibrium,  the 
AlphaScreen signal was measured on a EnSpire Alpha plate reader 
(PerkinElmer, Waltham, MA, USA).  
To test the effect on  TDP43-TAR32  binding, HET (0.05 nM-50 µM) was 
pre-incubated  with TDP-43 (0.2 nM) pre-bound to AlphaScreen anti-GST 
acceptor beads for 30 min at room temperature. DMSO concentration was less 
than 1% in each sample. Assays were initiated by the addition of bt-TAR-32 at 
10 nM  pre-bound to AlphaScreen strepavidin donor beads.  After incubation 
in the dark at room temperature for 3 h, the AlphaScreen signal was measured.  
IC50 values were determined from nonlinear regression fits of the data in 
GraphPad Prism. 
 
 
7.2.7 Proteasome assay 
 
100-mm plates of HeLa cells were separately treated with HET 10 µM and 
MG132 50 µM for 3 h whereas cells exposed to vehicle were utilized as 
control. Then, cells were abundantly washed, scraped off and harvested by 
centrifugation. The cell pellets were incubated with lysis buffer (PBS 1X, 
0.1% Igepal) for 5 min on ice and sonicated for two pulses of 10 s, at 30% 
output power, using a Vibracell sonicator. Lysates were then centrifuged for 
10 min at 10000g and 4°C to remove cellular debris, and the protein 
concentration was determined according to Bradford using BSA as standard. 
10 µg of each sample were diluted in 100 µl assay buffer (25 mM HEPES pH 
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7.4, 0.5 mM EDTA, 1 mM ATP) and fluorogenic peptides Suc-LLVY-amc 
(10 µM) was used to measure the chymotrypsin-like activities of the 20S 
proteasome. The release of  7-amino-4- methylcoumarin (amc) was monitored 
for 2 hours by emission at 460 nm (excitation 380 nm) using a multi-well plate 
Perkin Elmer LS55 Fluorescence Spectrometer. The experiments were 
performed in triplicate. 
 
 
7.2.7 HET influence on TDP43 cellular localization 
 
For immunofluorescence analysis, 4x104 cells/well were seeded on cover slips 
in 24-well plastic plates. After 24h, cells were treated with 10 µM HET (2h, 37 
°C) or 50 µM MG132 (3h, 37 °C) followed or not by heat shock treatment (1h, 
43°C). At the end of the treatments, cells were fixed in 4% paraformaldehyde 
(PFA) in PBS and subsequently permeabilized with 0.5% Triton X-100 for 15 
min. Cover slips were blocked with 1% bovine serum albumin (BSA) and 10% 
normal goat serum in PBS for 1 h and incubated with antibodies against TDP-
43 (1:2000; Sigma T1705) and HuR (1:200; Santa Cruz sc-5261), diluted in 
blocking buffer for 2 h at room temperature. Labelling was visualized with the 
fluorescently conjugated secondary antibodies DyLight 594 anti-rabbit and 
DyLight 488 anti-mouse (Jackson). All secondary antibodies were diluted 
1:2000 in PBS. Images were collected on a Zeiss LSM 510 confocal 
microscope using LSM software. Images shown are representative of multiple 
fields and triplicate cover slips per experiment. TDP-43 and HuR-positive SGs 
were counted in cultures where indicated. A minimum of 200 cells was 
counted across multiple fields of view (and multiple coverslips) for each 
treatment. The number of TDP-43 and HuR-positive SGs were counted in 
each cell. The total number of SGs was divided by the total number of cells to 
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provide a measure of mean SGs per cell. SGs were not observed in untreated 
cells. 
 
 
7.2.8 HET influence on TDP43 cellular aggregation 
 
HeLa cells were separately treated with 10 µM HET, 50 µM MG132 or 
vehicle (less than 1% DMSO) as control and incubated for 3 hours at 37°C in a 
5% CO2 atmosphere. Subsequently, cells were harvested and lysed by 
sonication as described above. Resulting lysates were centrifuged for 10 min 
at 10000g and 4°C to separate lysis buffer-soluble and insoluble fractions. 
Supernatants were collected and the protein concentration was determined 
according to Bradford using BSA as standard. The lysis buffer-insoluble 
fractions were re-suspended in a denaturing buffer (Tris 30mM, Urea 8M, 
thiourea 2 M and chaps 4%) and solubilisation was favoured over night under 
continuous shaking. Urea-soluble samples (5 µL) and lysis buffer-soluble 
extracts (10 µg) were resolved on a 10% SDS-PAGE gel and subjected to 
western blotting analysis using anti-TDP-43 antibody as reported above. The 
experiments were conducted in triplicate and GADPH antibody was used for 
normalization. 
 
7.3 In vitro and in cell Scalaradial interactome profiling 
 
7.3.1 In-Vitro Proteome Profiling 
 
SLD (1.5 mg, 3.5 µmol) has been incubated with tenfold molar excess of 2-(2-
amino-ethyl-disulfanyl)-ethyl-amine (TIOS) in ACN 0.5 % TEA. The reaction 
mixture was kept at room temperature for 30 minutes and product formation 
was monitored by using Agient 1100 series chromatograph equipped with 
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Phenomenex Jupiter C18 5µ 150 x 2.00 mm  column at the flow rate of 0.200 
ml/min. The elution was achieved  by means of a linear gradient from 5% to 
95% of B in 20 minutes (A: H2O, 0,1% TFA; B: 95% ACN, 5% H2O, 0,07% 
TFA) and monitored with an UV detector at the wavelength of 220 nm.  
The product formation was monitored (r.t. 25,5 min) by acquiring mass 
spectra on LCQ-DECA (Thermo Finnigan) equipped with an ESI source. 
The adduct, 2.7 µmol, was purified by means of the abovementioned 
chromatographic conditions, lyophilized and put in reaction with CDI-Agarose 
in 800 µl of ACN/NaHCO3. Immobilization yield was assessed by injecting 
small aliquots of the reaction mixture in HPLC and evaluating the reduction of 
SLD-TIOS peak areas. After 16h, the immobilization yield resulted to be 98 % 
and the matrix preparation was completed by adding to the solid support 400 
µl of 50 mM TRIS (Tris(2-aminoethyl)amine, pH=9) and maintaining the 
reaction under stirring for three hours. A control matrix was prepared in 
parallel by adding  2.1 µmol of TIOS, solubilized NaHCO3 50 mM, to 300 µl 
of CDI-Agarose. Linker immobilization was established analysing a small 
aliquot of beads with Kaiser test. Briefly, after extensive washings with 
ethanol,  20 µl of ninidrin (6% in ethanol), 20 µl di fenol (80% in ethanol), and 
20 µl of KCN were added  to the matrix and  the development of violet colour, 
indicating the presence of primary amines onto the beads surface, was detect 
after 5 min at 50°C. To the control matrix was added a solution containing 
acetic anhydride in DMF 5% TEA to acetylate free amines and a Kaiser test 
has been performed to verify the absence of free amines on modified resins.    
HeLa cells were grown and collected as already described (see chapter 7.1.4) 
and resuspended in ice-cooled PBS containing Igepal (0.1%) and a protease 
inhibitor cocktail. Cell lysis was achieved by dounce homogenation and 
cellular debris were removed by centrifugation at 10000g for 10 min at 4 °C. 
Protein concentration was determined using Bradford assay and adjusted to 1 
mg/ml. SLD-bound bead suspension (50 µL) and the same amount of the 
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control-matrix were separately incubated with 1 mg of HeLa total protein 
extract under continuous shaking (1h, 4°C). Beads were collected after 
centrifugation (1200 rpm, 3min, 4°C) and washed three times with PBS (pH 
7.4). The bound proteins were detached from the beads by breaking the 
disulphide bond contained into the TIOS linker with DTT 40 mM. The 
suspension was maintained at 37°C for 15 minutes to favourite disulphide 
bridge cleavage. SDS-PAGE loading buffer (60 mM Tris/HCl pH 6.8, 2% 
SDS, 0.001% bromophenol blue, 10% glycerol, 2% 2-mercaptoethanol)  was 
added to each sample and, after 5min at 95°C, denatured eluates were 
separated on 10% SDS-PAGE, and stained with Coomassie G-250 (Bio-Rad, 
Hercules, CA). SDS-PAGE gel lanes were cut and digested. The experiment 
has been repeated twice using an opportune control matrix bearing the linker 
without any metabolite. Each piece was washed with ultrapure water and 
CH3CN and subjected to in situ protein digestion as described by Shevchenko 
as already described (see chapter 7.1.4). Peptide samples re-suspended in  
formic acid (FA, 10%) and analysed with an ACQUITY UPLC system 
(Waters) coupled to a LTQ-Orbitrap XL (ThermoScientific).  
Peptides were separated on a 1.7 mm BEH C18 column (Waters) at a flow rate 
of 400 nL/min. Peptide elution was achieved with a linear gradient (solution 
A: 95 % H2O ,5 % CH3CN, 0.1% FA; solution B: 95 % CH3CN, 5 % H2O, 
0.1 % FA); 15–50% B over 55 min). MS and MS/MS data were acquired on 
high-performance liquid chromatography mass spectrometry system. The ten 
most intense doubly and triply charged peptide ions were chosen for 
fragmentation. Mascot generic files (mgf) for database search were generated 
by the software MassMatrix MS data file conversion. Database searches were 
carried out on the Mascot server (http://www.matrixscience.com/). The 
SwissProt database (release 2013_02, 6 February 2013, contains 539,165 
sequence entries comprising 191,456,931 amino acids abstracted from 216,632 
references) was employed. Searches were performed allowing  two missed 
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cleavages; carbamidomethyl (C) as fixed modification and oxidation (M) and 
phosphorylation (ST) as variable modifications; peptide tolerance 25 ppm; 
MS/MS tolerance 0.8 Da.  
 
 
7.3.2 Validation experiments 
 
After exposing SLD-bearing matrix and control matrix to the cellular lysate, 
eluted proteins were separated on 12% SDS-page and transferred to a 
nitrocellulose membrane.  
The membrane was incubated for 1 h in a blocking solution containing 25 mM 
Tris pH 8, 125mM NaCl, 0.05% Tween-20, 5% non-fat dried milk prior of 
exposition to primary antibodies raised against 14-3-3 ε (1:500) and PRX1 (1: 
500; Novus Biologicals). The recognition of specific epitopes was favourite 
overnight, at 4°C. Then, membrane was incubated for 1 h with an anti-rabbit 
peroxidase-conjugated secondary antibody (1:5000) (Sigma-Aldrich). 14-3-3- 
ε and PRX1 were detected by a chemo-luminescence detection system. 
14-3-3 ε and PRX1 were immobilized onto two different flow cells of a CM5 
sensor chip using standard amine coupling procedures. Phosphate–buffered 
saline, which consisted of 10 mM Na2HPO4 and 150 mM NaCl, pH 7.4, was 
used as running buffer. The carboxymethyl dextran surface was activated as 
already described and both proteins were diluted to a final concentration of 30 
ng/µl in 10 mM sodium acetate, pH 4.5 and injected separately onto the two 
flow cells. After protein injections a ∆RU of 9000 for PRX1 and a ∆RU of 
14000 was recordered. The activated carboxymethyl dextran surface was 
finally  blocked with a 7-min injection of 1.0 M ethanolamine-HCl, pH 8.5, at 
5 µl/min.  
SLD solutions (0.01-10 µM), were prepared in running buffer containing 1% 
of DMSO and injected at least three times. Since the dissociation back to 
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baseline was achieved within a reasonable time frame, no regeneration has 
been required. The interaction experiments were carried out at a flow rate of 
10 µl/min, employing a 3 min injection time. The dissociation time was set at 
600 seconds. Rate constants for associations (ka) dissociations (kd) and the 
dissociation constants (KD) were obtained by globally fitting data from 
injections of all concentrations, using the BIAevaluation software, using the 
simple 1:1 Langmuir binding model. 
 
 
7.3.3 Design and Synthesis of SLD-AZ 
 
SLD (1.5 mM) was coupled with 11-azido-3,6,9-trioxaundecan-1-amine 
(TRX-AZ, 15 mM) in ACN at 0.5% TEA for 1h at 25°C under stirring. 
Product formation has been monitored by RP-HPLC-UV at 220 nm using 
Agilent 1100 binary pump and Phenomenex column (Jupiter C18 150X2 mm 
5 µ) at 0.2 mL/min. Gradient was from 5% to 95% buffer B (A= 100% H2O 
and 0.1% TFA and B= 95% ACN, 5% H2O and 0.1% TFA) in 25 min. Mass 
spectra were acquired on LCQ-DECA ThermoFinnigan equipped with an ESI 
source. 
 
7.3.4 Click Chemistry Optimization 
 
SLD-AZ (1.25 mM) has been incubated for 1h with the linker 4-pentyn-1-
amine (PINA linker 2.50 mM) in 200 µL of PBS at pH 7.4 and less than 10% 
DMSO. Later on, with 100 µM CuSO4, 5 mM Na-L-(+)-Ascorbate and 100 
µM Tris-[(1-benzil-1,2,3-triazol-4-il)metal]amine (TBTA) under nitrogen and 
stirring. Product formation has been monitored by RP-HPLC-UV and MS 
analysis as reported above. 
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7.3.5 In-Situ Proteome Profiling  
 
To obtain an azide-coated matrix, 500 µL of CDI resin has been mixed with 5 
µmol of PINA linker in PBS buffer at pH of 7.4 for 3h at r.t.   
SLD-AZ (1 and 10 nmol) was incubated with HeLa cell lysate (obtained as 
described above) for 1 h at 4°C and then mixed with 50 µL of CDI-Agarose 
PINA-bearing matrix in presence of CuSO4, Na-L-(+)-Ascorbate and TBTA 
under nitrogen. As control, the experiment has been carried out in the same 
conditions using the TRX-Az as bait. After several washes in PBS buffer to 
remove the unbound proteins, SLD partners were eluted, separated by 12% 
SDS-PAGE and transferred onto a nitrocellulose membrane and probed as 
described above with antibodies directed against 14-3-3- ε and PRX1. 
 
7.3.5 Cell Viability Assay 
 
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay[219]. After SLD and SLD-AZ 
treatment in a concentration range from 1 µM to 10 µM, the mitochondrial-
dependent reduction of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) to formazan was used to assess the effect of the two 
molecules. 
 
 
7.3.6 In cell  fishing for partners  
 
Live HeLa cells were grown as described above, treated with 1 µM of SLD-
AZ and 1 µM of TRX-AZ for 6 hours and then washed with fresh media to 
remove the excess of drug which did not pass through cell membranes. Cell 
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were then lysed by dounce homogenation in a mixture containing PBS 0.1% 
Igepal and proteases inhibitors. 1 mg of lysates were then treated with 250 µM 
CuSO4, 2.5 mM Na-L-(+)-Ascorbate and 500 µM TBTA under nitrogen to 
promote Huisgen 1,3 cycloaddition on 10 µL of PINA derived CDI-Agarose 
beads for 45 mintes at 4°C. The same reaction was carried out both on the 
same sample without 2.5 mM Na-L-(+)-Ascorbate and on TRX-AZ treated 
cell lysates as negative controls. Pull-down samples were then separated by 
SDS-PAGE followed both by immune-blotting analysis as described above or 
Comassie staining. SDS-PAGE gel lanes were cut, digested and analysed as 
reported. Western blotting analysis on proteasome were carried out using 
primary monoclonal antibodies raised against α-7 proteasome subunit (1:500) 
and Psmc3 (1: 500) (Santa Cruz Biotechnology). Then, membrane was 
incubated for 1 h with an anti-mouse peroxidase-conjugated secondary 
antibody (1:5000). A chemo-luminescence detection system has been used. 
 
 
7.3.7 In cell  fishing for partners using Oleocanthal as bait 
 
Oleocanthal (1 mg, 3.3 µmol) was put in reaction with 33 µmol of TRX-AZ in 
ACN/NaHCO3. After 30 minutes at room temperature, a solution containing 
100 mM NaBH4 was added to the reaction mixture to allow imine reduction 
for 30 minutes at room temperature. Product formation (OLC-AZ) was 
monitored by injecting the reaction mixture in HPLC (Agilent 1100 series 
equipped with Jupiter Proteo C18 250x2.00 5µM ) and by eluting the adduct 
by means of  a linear gradient of  B from 10% to 95% in 25 minutes (solution 
A: TFA (0.1%); solution B: TFA (0.07 %), H2O (5%), CH3CN (95 %). MS 
analysis was performed using LCQ-Deca equipped with an ESI source. 
HeLa cells were grown as described, and treated with OLC-AZ or TRX-AZ at 
the concentration of 100 µM. After 3 h, supernatants were discarded and cells 
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were harvested and extensively washed prior cellular lysis performed as 
described.  
The coupling reaction of OLC-AZ and TRX-AZ to PINA-bearing matrix was 
performed by employing 100 µM CuSO4, 100 µM TBTA, 5mM Na-
Ascorbate, maintaining the suspensions under agitation for 45 minutes. 
After abundant washings in PBS, strictly bound proteins were eluted with 
SDS-PAGE loading buffer, separated by 10% SDS-PAGE and transferred 
onto nitrocellulose membrane.  
HSP90 was detected by incubating the membrane with the specific primary 
antibody (BD-Biosciences), overnight at 4°C and with an anti-mouse 
peroxidase-conjugated secondary antibody (1:5000; Thermo Scientific).  
Signals were detected using an enhanced chemiluminescent substrate (ECL) 
and LAS 4000 digital imaging system. 
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New insights in cCMP interaction profile by chemical 
proteomics: Experimental procedures 
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Materials 
 
N4‐(6‐Aminohexyl)cytidine‐ 3', 5'‐ cyclic monophosphate,  (4‐AH‐cCMP) 
was purchased from BIOLOG (Bremen, Germany). CDI‐activated resin and 
NHS‐activated agarose were obtained from Pierce. Protease inhibitor cocktail, 
complete mini, was from Roche Diagnostic. All the other chemicals (analysis 
grade) were purchased from commercial sources. For all experiments  high 
purity water, obtained from a Milli‐Q system (Millipore, Bedford, MA), was 
used.  
 
 
8.1 Pull down experiments using cCMP as bait 
 
500 µl of NHS-activated agarose were treated with a 5 mM solution of 
4‐AH‐cCMP in 1 ml of  NaHCO3 (50mM) at pH=8.5 under continuous 
shacking. The amount of immobilized 4-AH-cCMP was estimated by 
integrating the peaks of the free species after HPLC injections of supernatants 
at t=0 h, t=2 h and t=24 h. HPLC runs were carried out using LC 10AD VP, 
with a ZOBRAX Eclipse Plus C18 column (2.1x50mm, 1.8‐micron) and a 
solution of 95% H2O 5% acetonitrile (ACN)  0.1% formic acid (FA) was used 
as eluent at a flow rate of 0.150 mlmin‐1. After 24 hours the unbound cCMP 
was removed and a 500 mM Tris solution was added to the beads to quench 
unreacted functional groups onto beads surface. A control matrix was obtained 
incubating 500 µl of NHS-Activated Agarose with Tris buffer.  
HEK293 cells were collected centrifuging at 10000 rpm for 5 min and washed 
three times with phosphate-saline buffer (PBS, 50 mM natrium phosphate, 150 
mM NaCl). The obtained pellets were dissolved in ice-cool PBS containing 
0.1% Tween-20, supplemented with a protease inhibitor (1 complete min/15 
mL, Roche) and lysed by dounce homogenation. Cellular debris were removed 
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by centrifugation in an eppendorf table top centrifuge at 14000 rpm for 10 min 
at 4° C. Supernatants were carefully collected and pellets re-suspended in lysis 
buffer (500 µL) to increase the yield of the lysis procedure. The second 
supernatant, obtained by centrifugation (14000 rpm, 10 min, 4°C), was added 
to the first one and the protein concentration was determined using a Bradford 
assay. Prior to addition of the beads, the lysate was diluted to a final 
concentration of 1 mg/mL using lysis buffer. Depending on the yield of total 
protein from the extraction procedure, in each pull-down, 10 µL of  beads 
mixture was used per mg of protein. The obtained lysate-beads suspension was 
incubated for 1 h at 4°C by rotary shaking. Several washings with lysis buffer 
were carried out and proteins strictly bound to the resins were eluted by 
boiling them with an SDS sample loading buffer (Biorad) 
 
 
8.2 cCMP interactome profiling by competition experiments 
 
Cellular extracts were obtained  lysing HEK293 as described above, diluted to 
a final concentration of 1 mg/mL in lysis buffer. Two aliquots, each containing 
4 mg of proteins, were withdrawn and incubated separately with control 
matrix and cCMP-bearing matrix. To the remaining protein solution, ADP and 
GDP were added to a final concentration of 10 mM and the obtained mixture 
was further subdivided in 4 equal batches, each containing 4 mg of proteins. 
Aliquots were separately treated for 30 min at 4°C with (i) 5 µM cAMP, (ii) 5 
µM cGDP, (iii) cAMP and cGMP at the same concentrations. All batches were 
then incubated with 40 µL of cCMP-bearing matrix for 90 minutes at 4°C 
under continuous shaking. Later on, the unbound proteins were discarded and, 
after abundant washings with lysis buffer, the tightly bound proteins were 
eluted with SDS-sample loading buffer and separated by SDS-PAGE 
(Criterion XT Bis-Tris Precast Gels, BioRad). Resulting gel was stained with a 
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coomassie solution (GelCode Blue Stain Reagent - Pierce). For protein 
identification, coomassie stained gel was cut in small pieces and digested as 
previously reported. Briefly, each slice was reduced with 1,4-dithiothreitol 
(DTT, 10 mM) and alkylated with iodoacetamide (54 mM), then washed and 
rehydrated in trypsin solution (12 ngml-1) on ice for 1h. After the addition of 
ammonium bicarbonate (30 µL, 50 mM, pH 7.5), protein digestion was 
allowed to proceed overnight at 37°C. The supernatants were collected and 
peptides were extracted from the slice by using 100% CH3CN, dried in vacuo 
and resuspended in 10% FA. 
The peptide samples were analysed on an LTQ-Orbitrap XL instrument 
(Thermo, San Jose, CA) connected to an Agilent 1200 HPLC system. All 
columns were packed in house. The trap column was made using Aqua C18 
material (Phenomenex, Torrance, CA). Reprosil-pur C18 3 µm (Dr. Maisch, 
Ammerbuch-Entringen, Germany) was used for the 35 cm analytical column 
with 50 µm inner diameter. Solvent A consisted of 0.1M acetic acid in Milli- 
Q water, and solvent B consisted of 0.1M acetic acid in 80% acetonitrile. The 
flow rate of 5 µLmin-1 was passively split and reduced to an effective flow rate 
of 100 nLmin-1.  
The gradients were as follows: 60 min LC method, 10 min solvent A; 10-40% 
solvent B within 30 min; 100% solvent B for 2 min; 15 min solvent A.  
Nanospray was achieved using a distally coated fused silica emitter (New 
Objective, Cambridge, MA) (outer diameter, 360 µm; inner diameter, 20 µm; 
tip inner diameter, 10 µm) biased to 1.7 kV. The LTQ-Orbitrap mass 
spectrometer was operated in data-dependent mode, automatically switching 
between MS and MS/MS. Full-scan MS spectra (300–1500m/z) were acquired 
with a resolution of 60,000 at 400 m/z and accumulation to a target value of 
500,000. The five most intense peaks above a threshold of 500 were selected 
for collision-induced dissociation in the linear ion trap at a normalized 
collision energy of 35%. 
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Charge state screening was enabled, and precursors with unknown charge state 
or a charge state of 1 were excluded. The obtained data were processed with 
proteome discoverer 1.3 (Thermo, Bremen, Germany) using Mascot (version 
2.4.1 Matrix Science, London, UK) for database searching. The SwissProt 
human database was searched, allowing 2 missed cleavages, carbamidomethyl 
as fixed modification on cysteines, as well as oxidation (M) and 
phosphorylation (ST) as variable modifications. The peptide tolerance was set 
to 25 ppm and the MS/MS tolerance to 0.8 Da. Semi-quantitative analysis was 
performed by comparing PSMs. Only proteins identified with more than five 
PSMs were taken into account.  
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